https://trial.medpath.com/news/fda-accepts-sbla-for-susvimo-in-diabetic-eye-diseases-following-promising-phase-3-results 2024-07-23T14:45:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-sbla-for-susvimo-in-diabetic-eye-diseases-following-promising-phase-3-results 2024-07-23T14:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/an-isolated-viral-load-test-may-generate-false-positive-results-for-people-using-long-acting-prep 2024-07-23T04:07:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-isolated-viral-load-test-may-generate-false-positive-results-for-people-using-long-acting-prep 2024-07-23T04:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/long-acting-injectable-cabotegravir-for-hiv-prevention-is-safe-in-pregnancy 2024-07-23T04:07:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-acting-injectable-cabotegravir-for-hiv-prevention-is-safe-in-pregnancy 2024-07-23T04:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-topline-results-from-phase-2b-3-trial-of-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-preventative-monoclonal-antibody-for-infants 2024-07-23T04:07:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-topline-results-from-phase-2b-3-trial-of-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-preventative-monoclonal-antibody-for-infants 2024-07-23T04:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/ema-issues-precautionary-measures-for-valproate-use-in-male-patients-due-to-potential-neurodevelopmental-risks 2024-07-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-issues-precautionary-measures-for-valproate-use-in-male-patients-due-to-potential-neurodevelopmental-risks 2024-07-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/reunion-neuroscience-initiates-phase-2-trial-of-fast-acting-psychedelic-re104-for-postpartum-depression 2024-07-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reunion-neuroscience-initiates-phase-2-trial-of-fast-acting-psychedelic-re104-for-postpartum-depression 2024-07-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-epysqli-eculizumab-aagh-a-biosimilar-to-soliris 2024-07-22T20:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-epysqli-eculizumab-aagh-a-biosimilar-to-soliris 2024-07-22T20:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/synaptixbio-secures-second-fda-orphan-drug-designation-for-tubb4a-leukodystrophy-variant 2024-07-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synaptixbio-secures-second-fda-orphan-drug-designation-for-tubb4a-leukodystrophy-variant 2024-07-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/60-degrees-pharmaceuticals-initiates-clinical-trials-for-babesiosis-treatment 2024-07-22T08:14:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/60-degrees-pharmaceuticals-initiates-clinical-trials-for-babesiosis-treatment 2024-07-22T08:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-predictive-analytics-set-to-transform-cancer-patient-care-and-treatment-outcomes 2024-07-22T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-and-predictive-analytics-set-to-transform-cancer-patient-care-and-treatment-outcomes 2024-07-22T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-announces-fda-clearance-of-investigational-new-drug-application-for-zw191-a-novel-folate-receptor-targeted-topoisomerase-i-inhibitor-antibody-drug-conjugate 2024-07-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-announces-fda-clearance-of-investigational-new-drug-application-for-zw191-a-novel-folate-receptor-targeted-topoisomerase-i-inhibitor-antibody-drug-conjugate 2024-07-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-new-heart-failure-implant-its-breakthrough-device 2024-07-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-new-heart-failure-implant-its-breakthrough-device 2024-07-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/once-daily-gildeuretinol-acetate-shows-promise-in-halting-early-stage-stargardt-disease-progression 2024-07-21T18:48:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/once-daily-gildeuretinol-acetate-shows-promise-in-halting-early-stage-stargardt-disease-progression 2024-07-21T18:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-receives-fda-positive-feedback-for-expanding-gene-therapy-trial-to-include-ftd-c9orf72-patients 2024-07-19T22:00:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/passage-bio-receives-fda-positive-feedback-for-expanding-gene-therapy-trial-to-include-ftd-c9orf72-patients 2024-07-19T22:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zituvimet-xr-sitagliptin-and-metformin-hydrochloride-extended-release-tablets-for-adults-with-type-2-diabetes 2024-07-19T19:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zituvimet-xr-sitagliptin-and-metformin-hydrochloride-extended-release-tablets-for-adults-with-type-2-diabetes 2024-07-19T19:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-data-explosion-industry-grapples-with-283-increase-in-phase-iii-data-collection 2024-07-19T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-data-explosion-industry-grapples-with-283-increase-in-phase-iii-data-collection 2024-07-19T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rezatapopt-takes-aim-at-previously-untargetable-p53 2024-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rezatapopt-takes-aim-at-previously-untargetable-p53 2024-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-commission-president-unveils-ambitious-2025-biotech-act-to-boost-european-life-sciences 2024-07-18T22:18:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-commission-president-unveils-ambitious-2025-biotech-act-to-boost-european-life-sciences 2024-07-18T22:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/phathom-pharmaceuticals-announces-fda-approval-of-voquezna-vonoprazan-tablets-for-the-relief-of-heartburn-associated-with-non-erosive-gerd-in-adults 2024-07-18T21:07:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phathom-pharmaceuticals-announces-fda-approval-of-voquezna-vonoprazan-tablets-for-the-relief-of-heartburn-associated-with-non-erosive-gerd-in-adults 2024-07-18T21:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advises-against-accelerated-approval-for-botensilimab-balstilimab-in-mss-colorectal-cancer-despite-phase-3-advancement 2024-07-18T15:16:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advises-against-accelerated-approval-for-botensilimab-balstilimab-in-mss-colorectal-cancer-despite-phase-3-advancement 2024-07-18T15:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-helios-trial-shows-promise-for-otx-tki-in-non-proliferative-diabetic-retinopathy 2024-07-18T13:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1-helios-trial-shows-promise-for-otx-tki-in-non-proliferative-diabetic-retinopathy 2024-07-18T13:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/asrs-2024-examining-real-world-use-of-faricimab-through-the-faretina 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asrs-2024-examining-real-world-use-of-faricimab-through-the-faretina 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-achieves-significant-pipeline-progress-in-first-half-of-2024 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-achieves-significant-pipeline-progress-in-first-half-of-2024 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-clinical-success-rates-drop-to-6-7-amid-evolving-r-d-landscape 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-clinical-success-rates-drop-to-6-7-amid-evolving-r-d-landscape 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-develop-breakthrough-anti-ageing-drug-that-extends-lifespan-by-25 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientists-develop-breakthrough-anti-ageing-drug-that-extends-lifespan-by-25 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/trofinetide-shows-promise-as-a-treatment-for-rett-syndrome 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trofinetide-shows-promise-as-a-treatment-for-rett-syndrome 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-advances-overcoming-challenges-in-solid-tumors-and-enhancing-safety-through-innovative-engineering 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-advances-overcoming-challenges-in-solid-tumors-and-enhancing-safety-through-innovative-engineering 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atara-biotherapeutics-announces-u-s-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-cel-r-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-07-17T23:07:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atara-biotherapeutics-announces-u-s-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-cel-r-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-07-17T23:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/brentuximab-vedotin-triplet-shows-significant-survival-benefits-in-relapsed-refractory-dlbcl 2024-07-17T19:25:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brentuximab-vedotin-triplet-shows-significant-survival-benefits-in-relapsed-refractory-dlbcl 2024-07-17T19:25:02+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-arizona-commercial-use-of-new-cancer-therapy-shows-promising-results 2024-07-17T15:21:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-arizona-commercial-use-of-new-cancer-therapy-shows-promising-results 2024-07-17T15:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-post-transcriptional-rna-modification-with-a-first-to-clinic-mettl3-inhibitor-stc15 2024-07-17T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-post-transcriptional-rna-modification-with-a-first-to-clinic-mettl3-inhibitor-stc15 2024-07-17T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/orexo-receives-a-complete-response-letter-regarding-the-nda-for-ox124-a-high-dose-naloxone-rescue-medication-in-development-for-opioid-overdose 2024-07-17T00:07:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orexo-receives-a-complete-response-letter-regarding-the-nda-for-ox124-a-high-dose-naloxone-rescue-medication-in-development-for-opioid-overdose 2024-07-17T00:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-investigational-new-drug-application-for-muscular-dystrophy-treatment-from-university-of-minnesota-startup-myogenica 2024-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-investigational-new-drug-application-for-muscular-dystrophy-treatment-from-university-of-minnesota-startup-myogenica 2024-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-novel-b7-h3-targeting-adc-in-sclc 2024-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-novel-b7-h3-targeting-adc-in-sclc 2024-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-pharmaceuticals-receives-december-20-2024-pdufa-goal-date-for-sotagliflozin-type-1-diabetes-nda-resubmission 2024-07-16T21:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-pharmaceuticals-receives-december-20-2024-pdufa-goal-date-for-sotagliflozin-type-1-diabetes-nda-resubmission 2024-07-16T21:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/tenosynovial-giant-cell-tumors-treatment-market-to-see-significant-growth-by-2034 2024-07-16T05:48:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenosynovial-giant-cell-tumors-treatment-market-to-see-significant-growth-by-2034 2024-07-16T05:48:25+00:00 weekly 0.7 https://trial.medpath.com/news/global-clinical-trials-landscape-reveals-promising-advances-in-non-small-cell-lung-cancer-treatment 2024-07-16T01:35:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-clinical-trials-landscape-reveals-promising-advances-in-non-small-cell-lung-cancer-treatment 2024-07-16T01:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/more-men-with-advanced-prostate-cancer-could-benefit-from-precision-drug-olaparib 2024-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-men-with-advanced-prostate-cancer-could-benefit-from-precision-drug-olaparib 2024-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-completes-end-of-phase-2-meeting-for-annamycin-plus-cytarabine-in-aml 2024-07-15T15:27:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-completes-end-of-phase-2-meeting-for-annamycin-plus-cytarabine-in-aml 2024-07-15T15:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/eton-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-07-15T04:07:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eton-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-07-15T04:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/dare-bioscience-publishes-positive-phase-2b-results-for-topical-sildenafil-cream-in-female-sexual-arousal-disorder 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dare-bioscience-publishes-positive-phase-2b-results-for-topical-sildenafil-cream-in-female-sexual-arousal-disorder 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-adagrasib-with-cetuximab-for-kras-g12c-mutated-advanced-colorectal-cancer 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-adagrasib-with-cetuximab-for-kras-g12c-mutated-advanced-colorectal-cancer 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maralixibat-shows-promise-in-treating-progressive-familial-intrahepatic-cholestasis 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maralixibat-shows-promise-in-treating-progressive-familial-intrahepatic-cholestasis 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-for-stiff-person-syndrome-granted-fast-track-designation-from-fda-fox-news 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-for-stiff-person-syndrome-granted-fast-track-designation-from-fda-fox-news 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-alzheimer-s-drug-obtains-fda-approval-here-s-why-the-stock-isn-t-taking-off 2024-07-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-alzheimer-s-drug-obtains-fda-approval-here-s-why-the-stock-isn-t-taking-off 2024-07-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/msd-completes-3-billion-acquisition-of-eyebio-gaining-novel-retinal-disease-candidate-restoret 2024-07-12T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msd-completes-3-billion-acquisition-of-eyebio-gaining-novel-retinal-disease-candidate-restoret 2024-07-12T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-approaches-reshape-rare-disease-drug-development-experts-outline-path-to-success 2024-07-12T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-approaches-reshape-rare-disease-drug-development-experts-outline-path-to-success 2024-07-12T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-a 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-a 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/w-t7-shows-encouraging-response-rate-manageable 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/w-t7-shows-encouraging-response-rate-manageable 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-immunotherapy-combination-shows-promise-against-common-colorectal-cancer-in-phase-1-trial 2024-07-11T13:14:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-immunotherapy-combination-shows-promise-against-common-colorectal-cancer-in-phase-1-trial 2024-07-11T13:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/is-eli-lilly-lly-a-buy-on-tirzepatide-success-in-sleep-apnea 2024-07-11T12:43:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-eli-lilly-lly-a-buy-on-tirzepatide-success-in-sleep-apnea 2024-07-11T12:43:32+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-btk-degraders-show-promise-in-treating-resistant-b-cell-malignancies 2024-07-11T09:00:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emerging-btk-degraders-show-promise-in-treating-resistant-b-cell-malignancies 2024-07-11T09:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/fresh-take-on-how-to-conduct-rare-disease-clinical-trials 2024-07-11T09:00:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fresh-take-on-how-to-conduct-rare-disease-clinical-trials 2024-07-11T09:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-receives-fda-approval-for-phase-2-obesity-trial-of-bio101-to-address-muscle-loss-in-glp-1-therapy 2024-07-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biophytis-receives-fda-approval-for-phase-2-obesity-trial-of-bio101-to-address-muscle-loss-in-glp-1-therapy 2024-07-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genai-poised-to-transform-pharmaceutical-medical-writing-despite-implementation-challenges 2024-07-11T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genai-poised-to-transform-pharmaceutical-medical-writing-despite-implementation-challenges 2024-07-11T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-cancer-vaccines-clinical-trials-market-opportunity 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrna-cancer-vaccines-clinical-trials-market-opportunity 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-inc-announces-change-to-auditor-financial-post 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-inc-announces-change-to-auditor-financial-post 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/amivantamab-plus-lazertinib-improves-pfs-over 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amivantamab-plus-lazertinib-improves-pfs-over 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/delhi-high-court-bans-zydus-pertuzumab-biosimilar-sigrima-in-patent-infringement-case 2024-07-10T23:51:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delhi-high-court-bans-zydus-pertuzumab-biosimilar-sigrima-in-patent-infringement-case 2024-07-10T23:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-and-challenges-in-renal-cell-carcinoma-treatment 2024-07-10T16:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-and-challenges-in-renal-cell-carcinoma-treatment 2024-07-10T16:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/hybryte-shows-promising-results-in-early-stage-cutaneous-t-cell-lymphoma-treatment 2024-07-10T16:00:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hybryte-shows-promising-results-in-early-stage-cutaneous-t-cell-lymphoma-treatment 2024-07-10T16:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-acquires-phase-3-ready-glp-1-receptor-antagonist-avexitide-for-hyperinsulinemic-hypoglycemia 2024-07-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amylyx-acquires-phase-3-ready-glp-1-receptor-antagonist-avexitide-for-hyperinsulinemic-hypoglycemia 2024-07-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-grants-orphan-designations-for-rare-disease-treatments-in-pulmonary-fibrosis-and-b-cell-lymphoma 2024-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-grants-orphan-designations-for-rare-disease-treatments-in-pulmonary-fibrosis-and-b-cell-lymphoma 2024-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-safety-findings-among-persons-aged-60-years 2024-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-safety-findings-among-persons-aged-60-years 2024-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-arcutis-zoryve-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age 2024-07-09T22:07:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-arcutis-zoryve-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age 2024-07-09T22:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-generic-methimazole-solution-for-feline-hyperthyroidism-treatment 2024-07-09T16:21:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-generic-methimazole-solution-for-feline-hyperthyroidism-treatment 2024-07-09T16:21:18+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-advances-in-clinical-trials-and-expands-into-obesity-treatment 2024-07-09T09:21:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-path-holdings-advances-in-clinical-trials-and-expands-into-obesity-treatment 2024-07-09T09:21:34+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-initiates-phase-3-trial-of-int230-6-for-metastatic-sarcoma 2024-07-09T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intensity-therapeutics-initiates-phase-3-trial-of-int230-6-for-metastatic-sarcoma 2024-07-09T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/nda-resubmission-planned-for-rivoceranib-camrelizumab-in-onclive 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nda-resubmission-planned-for-rivoceranib-camrelizumab-in-onclive 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/interius-biotherapeutics-receives-hrec-approval-and-ctn-clearance-from-the-tga-to-commence-a-phase-1-clinical-trial-for-its-first-in-class-in-vivo-car-therapeutic-for-b-cell-malignancies 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interius-biotherapeutics-receives-hrec-approval-and-ctn-clearance-from-the-tga-to-commence-a-phase-1-clinical-trial-for-its-first-in-class-in-vivo-car-therapeutic-for-b-cell-malignancies 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-s-paradigm-als-clinical-trial-demonstrates-up-to-73-improved-complication-free-survival-following-statistically-significant-slowing-of-disease-progression 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-s-paradigm-als-clinical-trial-demonstrates-up-to-73-improved-complication-free-survival-following-statistically-significant-slowing-of-disease-progression 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/flot-perioperative-chemotherapy-extends-survival-over-cross-protocol-in-esophageal-cancer 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/flot-perioperative-chemotherapy-extends-survival-over-cross-protocol-in-esophageal-cancer 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparing-long-term-data-for-io-io-and-io-tki-in-favorable-risk-metastatic-renal-cell-carcinoma 2024-07-08T21:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparing-long-term-data-for-io-io-and-io-tki-in-favorable-risk-metastatic-renal-cell-carcinoma 2024-07-08T21:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/global-breast-cancer-therapeutics-market-expected-to-reach-78-61-billion-by-2033 2024-07-08T21:21:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-breast-cancer-therapeutics-market-expected-to-reach-78-61-billion-by-2033 2024-07-08T21:21:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-225ac-fl-020-for-metastatic-castration-resistant-prostate-cancer 2024-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-225ac-fl-020-for-metastatic-castration-resistant-prostate-cancer 2024-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-dominates-ai-driven-drug-discovery-patent-landscape-reshaping-pharmaceutical-r-d 2024-07-06T20:12:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-dominates-ai-driven-drug-discovery-patent-landscape-reshaping-pharmaceutical-r-d 2024-07-06T20:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/cnipa-upholds-vortioxetine-crystal-form-patent-in-landmark-decision-for-pharmaceutical-ip-in-china 2024-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cnipa-upholds-vortioxetine-crystal-form-patent-in-landmark-decision-for-pharmaceutical-ip-in-china 2024-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-genentechs-vabysmo-prefilled-syringe-pfs-for-three-leading-causes-of-vision-loss 2024-07-04T20:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-genentechs-vabysmo-prefilled-syringe-pfs-for-three-leading-causes-of-vision-loss 2024-07-04T20:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-dostarlimab-expands-development-portfolio-to-target-multiple-advanced-cancers 2024-07-04T09:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-dostarlimab-expands-development-portfolio-to-target-multiple-advanced-cancers 2024-07-04T09:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/uk-survey-reveals-8-year-treatment-delay-and-severe-impact-of-chronic-hand-eczema-on-daily-life 2024-07-04T08:10:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-survey-reveals-8-year-treatment-delay-and-severe-impact-of-chronic-hand-eczema-on-daily-life 2024-07-04T08:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-drugs-ozempic-and-wegovy-linked-to-increased-risk-of-blinding-eye-condition-in-new-study 2024-07-03T15:00:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-drugs-ozempic-and-wegovy-linked-to-increased-risk-of-blinding-eye-condition-in-new-study 2024-07-03T15:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-breakthrough-twice-yearly-injection-shows-100-efficacy-in-preventing-infection 2024-07-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hiv-breakthrough-twice-yearly-injection-shows-100-efficacy-in-preventing-infection 2024-07-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-stock-swells-after-phase-iii-parkinson-s-subgroup 2024-07-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annovis-stock-swells-after-phase-iii-parkinson-s-subgroup 2024-07-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kisunla-donanemab-azbt-for-the-treatment-of-early-symptomatic-alzheimer-s-disease 2024-07-02T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-kisunla-donanemab-azbt-for-the-treatment-of-early-symptomatic-alzheimer-s-disease 2024-07-02T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-endometrial-cancer-therapies-expanding-treatment-options 2024-07-02T19:00:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-endometrial-cancer-therapies-expanding-treatment-options 2024-07-02T19:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-releases-new-draft-guidance-on-diversity-action-plans-for-clinical-studies 2024-07-02T11:45:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-releases-new-draft-guidance-on-diversity-action-plans-for-clinical-studies 2024-07-02T11:45:50+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-announces-fda-acceptance-of-new-drug-application-for-vanzacaftor-tezacaftor-deutivacaftor-a-next-in-class-triple-combination-treatment-for-cystic-fibrosis 2024-07-02T05:07:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-announces-fda-acceptance-of-new-drug-application-for-vanzacaftor-tezacaftor-deutivacaftor-a-next-in-class-triple-combination-treatment-for-cystic-fibrosis 2024-07-02T05:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-in-oncology-april-june-2024-blog-aacr 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approvals-in-oncology-april-june-2024-blog-aacr 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dementia-global-clinical-trials-review-2024-comparative-scenario-of-completed-and-uncompleted-terminated-suspended-withdrawn-trials 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dementia-global-clinical-trials-review-2024-comparative-scenario-of-completed-and-uncompleted-terminated-suspended-withdrawn-trials 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-second-alzheimers-drug-that-can-slow-onset-of-disease-alzheimer-s-the-guardian 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-second-alzheimers-drug-that-can-slow-onset-of-disease-alzheimer-s-the-guardian 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-to-know-about-the-next-generation-of-covid-19-vaccines-abc-news 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-to-know-about-the-next-generation-of-covid-19-vaccines-abc-news 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-generates-os-benefit-in-r-r-myeloma-after-1-prior-therapy 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilta-cel-generates-os-benefit-in-r-r-myeloma-after-1-prior-therapy 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ahzantive-aflibercept-mrbb-a-biosimilar-to-eylea 2024-07-01T23:07:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ahzantive-aflibercept-mrbb-a-biosimilar-to-eylea 2024-07-01T23:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/eirion-therapeutics-launches-first-in-human-clinical-trial-for-et-02-a-novel-treatment-for-androgenic-alopecia 2024-07-01T22:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eirion-therapeutics-launches-first-in-human-clinical-trial-for-et-02-a-novel-treatment-for-androgenic-alopecia 2024-07-01T22:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nypozi-filgrastim-txid-a-biosimilar-to-neupogen 2024-07-01T21:07:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nypozi-filgrastim-txid-a-biosimilar-to-neupogen 2024-07-01T21:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ianalumab-advances-in-phase-3-trial-for-lupus-nephritis-as-cdsco-approves-protocol-amendment 2024-07-01T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-ianalumab-advances-in-phase-3-trial-for-lupus-nephritis-as-cdsco-approves-protocol-amendment 2024-07-01T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-completes-submission-of-new-drug-application-to-the-fda-for-mirdametinib-for-the-treatment-of-children-and-adults-with-nf1-pn 2024-07-01T06:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-therapeutics-completes-submission-of-new-drug-application-to-the-fda-for-mirdametinib-for-the-treatment-of-children-and-adults-with-nf1-pn 2024-07-01T06:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pyzchiva-ustekinumab-ttwe-a-biosimilar-to-stelara 2024-07-01T05:07:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pyzchiva-ustekinumab-ttwe-a-biosimilar-to-stelara 2024-07-01T05:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-data-analytics-could-reduce-clinical-trial-failure-rates-by-20-quanthealth-ceo-reports 2024-07-01T01:29:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-and-data-analytics-could-reduce-clinical-trial-failure-rates-by-20-quanthealth-ceo-reports 2024-07-01T01:29:50+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-nivolumab-plus-ipilimumab-reduces 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-nivolumab-plus-ipilimumab-reduces 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lynparza-and-imfinzi-combination-recommended-for-eu-approval-in-endometrial-cancer-treatment 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lynparza-and-imfinzi-combination-recommended-for-eu-approval-in-endometrial-cancer-treatment 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biologics-for-chronic-rhinosinusitis-with-nasal-polyps-pubmed 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biologics-for-chronic-rhinosinusitis-with-nasal-polyps-pubmed 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/improving-clinical-trial-informed-consent-new-strategies-to-enhance-patient-understanding-and-trial-success 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-clinical-trial-informed-consent-new-strategies-to-enhance-patient-understanding-and-trial-success 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kalivir-immunotherapeutics-announces-fda-clearance-of-investigational-new-drug-ind-for-oncolytic-immunotherapy-vet3-tgi-for-solid-tumors 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalivir-immunotherapeutics-announces-fda-clearance-of-investigational-new-drug-ind-for-oncolytic-immunotherapy-vet3-tgi-for-solid-tumors 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bionic-leg-makes-walking-quicker-and-easier-for-amputees-trial-shows-medical-research-the-guardian 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bionic-leg-makes-walking-quicker-and-easier-for-amputees-trial-shows-medical-research-the-guardian 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ivabradine-s-impact-on-heart-failure-with-reduced-ejection-fraction-a-systematic-review-and-meta-analysis 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ivabradine-s-impact-on-heart-failure-with-reduced-ejection-fraction-a-systematic-review-and-meta-analysis 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kashiv-biosciences-enters-into-exclusive-licensing-agreement-with 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kashiv-biosciences-enters-into-exclusive-licensing-agreement-with 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-zealand-patient-becomes-first-globally-to-receive-gene-therapy-for-facioscapulohumeral-muscular-dystrophy 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-zealand-patient-becomes-first-globally-to-receive-gene-therapy-for-facioscapulohumeral-muscular-dystrophy 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tepylute-thiotepa-ready-to-dilute-injectable-formulation-to-treat-breast-cancer-and-ovarian-cancer 2024-06-28T22:06:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-tepylute-thiotepa-ready-to-dilute-injectable-formulation-to-treat-breast-cancer-and-ovarian-cancer 2024-06-28T22:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/infection-risk-with-btk-inhibitors-low-new-cll-study-finds 2024-06-28T16:19:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/infection-risk-with-btk-inhibitors-low-new-cll-study-finds 2024-06-28T16:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-multiple-barriers-limiting-biologic-access-for-psoriasis-patients 2024-06-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-multiple-barriers-limiting-biologic-access-for-psoriasis-patients 2024-06-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-status-to-spinogenix-s-spg601-for-fragile-x-syndrome 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-status-to-spinogenix-s-spg601-for-fragile-x-syndrome 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/drug-farm-receives-fda-ind-clearance-for-first-in-class-alpk1-inhibitor-df-003-in-rosah-syndrome 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-farm-receives-fda-ind-clearance-for-first-in-class-alpk1-inhibitor-df-003-in-rosah-syndrome 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anokion-reveals-promising-phase-1b-2-data-on-kan-101-for-celiac-disease 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anokion-reveals-promising-phase-1b-2-data-on-kan-101-for-celiac-disease 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-non-renewal-of-authorisation-of-duchenne 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-recommends-non-renewal-of-authorisation-of-duchenne 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/epkinly-epcoritamab-bysp-approved-by-u-s-fda-for-patients-with-relapsed-or-refractory-r-r-follicular-lymphoma-fl 2024-06-27T04:06:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epkinly-epcoritamab-bysp-approved-by-u-s-fda-for-patients-with-relapsed-or-refractory-r-r-follicular-lymphoma-fl 2024-06-27T04:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/uk-and-denmark-approve-csl-s-hemgenix-gene-therapy-for-haemophilia-b-with-novel-reimbursement-models 2024-06-27T02:18:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-and-denmark-approve-csl-s-hemgenix-gene-therapy-for-haemophilia-b-with-novel-reimbursement-models 2024-06-27T02:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/reunion-neuroscience-advances-re104-psychedelic-treatment-for-postpartum-depression-with-103m-funding 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reunion-neuroscience-advances-re104-psychedelic-treatment-for-postpartum-depression-with-103m-funding 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/slated-capricor-fda-meeting-to-focus-on-dmd-therapy-deramiocel 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/slated-capricor-fda-meeting-to-focus-on-dmd-therapy-deramiocel 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/exosome-based-cancer-therapy-advances-from-cell-free-treatment-to-targeted-drug-delivery 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exosome-based-cancer-therapy-advances-from-cell-free-treatment-to-targeted-drug-delivery 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-clinical-trial-underway-for-qtx3046-in-krasg12d-mutated-advanced-solid-tumors 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1-clinical-trial-underway-for-qtx3046-in-krasg12d-mutated-advanced-solid-tumors 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/huadong-medicine-reports-positive-phase-i-results-for-oral-glp-1-receptor-agonist-hdm1002 2024-06-26T13:10:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/huadong-medicine-reports-positive-phase-i-results-for-oral-glp-1-receptor-agonist-hdm1002 2024-06-26T13:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-makes-significant-progress-in-mental-health-treatment-development 2024-06-26T12:30:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-makes-significant-progress-in-mental-health-treatment-development 2024-06-26T12:30:32+00:00 weekly 0.7 https://trial.medpath.com/news/encell-s-mesenchymal-stem-cell-therapy-shows-promise-in-first-in-human-trial-for-charcot-marie-tooth-disease 2024-06-26T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/encell-s-mesenchymal-stem-cell-therapy-shows-promise-in-first-in-human-trial-for-charcot-marie-tooth-disease 2024-06-26T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer 2024-06-26T04:06:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer 2024-06-26T04:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/star-therapeutics-presents-clinical-data-for-vga039-a-subcutaneous 2024-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/star-therapeutics-presents-clinical-data-for-vga039-a-subcutaneous 2024-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-announces-us-fda-approval-of-ohtuvayretm-ensifentrine 2024-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-announces-us-fda-approval-of-ohtuvayretm-ensifentrine 2024-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/industry-survey-reveals-healthcare-mistrust-as-major-barrier-to-clinical-trial-diversity 2024-06-25T22:08:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/industry-survey-reveals-healthcare-mistrust-as-major-barrier-to-clinical-trial-diversity 2024-06-25T22:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-provides-u-s-regulatory-update-on-abbv-951-foscarbidopa-foslevodopa 2024-06-25T21:06:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-provides-u-s-regulatory-update-on-abbv-951-foscarbidopa-foslevodopa 2024-06-25T21:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-brexpiprazole-sertraline-combination-for-ptsd-review-marking-first-potential-new-treatment-in-over-20-years 2024-06-25T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-brexpiprazole-sertraline-combination-for-ptsd-review-marking-first-potential-new-treatment-in-over-20-years 2024-06-25T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-advances-parkinson-s-disease-treatment-with-phase-2-trial-of-ab-1005-gene-therapy 2024-06-25T11:55:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/askbio-advances-parkinson-s-disease-treatment-with-phase-2-trial-of-ab-1005-gene-therapy 2024-06-25T11:55:54+00:00 weekly 0.7 https://trial.medpath.com/news/generative-ai-poised-to-transform-clinical-trial-efficiency-with-40-faster-regulatory-submissions 2024-06-25T03:29:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/generative-ai-poised-to-transform-clinical-trial-efficiency-with-40-faster-regulatory-submissions 2024-06-25T03:29:52+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-olezarsen-new-drug-application-accepted-for-priority-review-and-enrollment-in-phase-3-shtg-program-completed 2024-06-25T01:06:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-olezarsen-new-drug-application-accepted-for-priority-review-and-enrollment-in-phase-3-shtg-program-completed 2024-06-25T01:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/riliprubart-shows-promise-as-first-in-class-treatment-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/riliprubart-shows-promise-as-first-in-class-treatment-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/n-power-medicine-secures-series-b-funding-to-enhance-oncology-clinical-trials-access 2024-06-24T16:54:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/n-power-medicine-secures-series-b-funding-to-enhance-oncology-clinical-trials-access 2024-06-24T16:54:32+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-helped-women-lose-more-weight-than-men-with-the-same-heart-condition-study-says 2024-06-24T14:42:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wegovy-helped-women-lose-more-weight-than-men-with-the-same-heart-condition-study-says 2024-06-24T14:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/sen-jam-pharmaceutical-completes-enrollment-for-phase-2-upper-respiratory-infection-covid-therapeutic 2024-06-24T13:56:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sen-jam-pharmaceutical-completes-enrollment-for-phase-2-upper-respiratory-infection-covid-therapeutic 2024-06-24T13:56:03+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-reduces-kidney-disease-risk-by-24-in-landmark-flow-trial-for-type-2-diabetes-patients 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-reduces-kidney-disease-risk-by-24-in-landmark-flow-trial-for-type-2-diabetes-patients 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-gives-guidance-on-seven-clinical-readouts-within-18-months 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recursion-gives-guidance-on-seven-clinical-readouts-within-18-months 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-announces-ema-has-initiated-review-of-the-elevidys 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-announces-ema-has-initiated-review-of-the-elevidys 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-obesity-drugs-target-muscle-preservation-and-enhanced-efficacy-beyond-glp-1-mechanisms 2024-06-23T17:46:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-obesity-drugs-target-muscle-preservation-and-enhanced-efficacy-beyond-glp-1-mechanisms 2024-06-23T17:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/inhale-3-trial-shows-inhaled-insulin-improves-glycemic-control-in-type-1-diabetes-patients 2024-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inhale-3-trial-shows-inhaled-insulin-improves-glycemic-control-in-type-1-diabetes-patients 2024-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-receives-40th-fda-approval-for-advanced-endometrial-cancer-treatment 2024-06-21T17:11:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keytruda-receives-40th-fda-approval-for-advanced-endometrial-cancer-treatment 2024-06-21T17:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-panel-unanimously-recommends-approval-of-lilly-s-alzheimer-s-drug-donanemab 2024-06-21T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advisory-panel-unanimously-recommends-approval-of-lilly-s-alzheimer-s-drug-donanemab 2024-06-21T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-advances-dual-regulatory-milestones-with-tafasitamab-bla-acceptance-and-bcl2-inhibitor-icp-248-clinical-trial-approval-in-china 2024-06-21T09:56:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-advances-dual-regulatory-milestones-with-tafasitamab-bla-acceptance-and-bcl2-inhibitor-icp-248-clinical-trial-approval-in-china 2024-06-21T09:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-vyvgart-hytrulo-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-vyvgart-hytrulo-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-s-vx-880-stem-cell-therapy-achieves-insulin-independence-in-type-1-diabetes-patients 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-s-vx-880-stem-cell-therapy-achieves-insulin-independence-in-type-1-diabetes-patients 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-intends-to-seek-accelerated-approval-for-mpsiii 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-intends-to-seek-accelerated-approval-for-mpsiii 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-surges-on-expanded-approval-of-muscular-dystrophy-drug 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-surges-on-expanded-approval-of-muscular-dystrophy-drug 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rapafusyn-pharmaceuticals-raises-28-million-series-a-to-advance-non-degrading-molecular-glue-platform 2024-06-20T18:23:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapafusyn-pharmaceuticals-raises-28-million-series-a-to-advance-non-degrading-molecular-glue-platform 2024-06-20T18:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/cocrystal-pharma-s-cc-42344-shows-activity-against-h5n1-avian-influenza-in-preclinical-studies 2024-06-20T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cocrystal-pharma-s-cc-42344-shows-activity-against-h5n1-avian-influenza-in-preclinical-studies 2024-06-20T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ionctura-secures-eur80-million-series-b-to-advance-pi3kd-cancer-therapy-through-phase-ii-trials 2024-06-20T02:03:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionctura-secures-eur80-million-series-b-to-advance-pi3kd-cancer-therapy-through-phase-ii-trials 2024-06-20T02:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/paxlovid-reduces-risk-of-long-covid-and-post-acute-hospitalization-or-death-in-high-risk-patients 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paxlovid-reduces-risk-of-long-covid-and-post-acute-hospitalization-or-death-in-high-risk-patients 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/open-surgery-outperforms-minimally-invasive-techniques-in-cervical-cancer-treatment-study-finds 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/open-surgery-outperforms-minimally-invasive-techniques-in-cervical-cancer-treatment-study-finds 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-wins-full-approval-and-label-expansion-for-dmd-gene-therapy-biospace 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-wins-full-approval-and-label-expansion-for-dmd-gene-therapy-biospace 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-maintains-clinical-benefit-in-myelofibrosis-patients-despite-treatment-related-anemia 2024-06-19T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-maintains-clinical-benefit-in-myelofibrosis-patients-despite-treatment-related-anemia 2024-06-19T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-explores-brentuximab-vedotin-for-systemic-sclerosis-treatment-in-development-pipeline 2024-06-19T09:28:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-explores-brentuximab-vedotin-for-systemic-sclerosis-treatment-in-development-pipeline 2024-06-19T09:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-blood-test-shows-promise-for-early-parkinson-s-detection-with-100-accuracy 2024-06-19T02:02:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-blood-test-shows-promise-for-early-parkinson-s-detection-with-100-accuracy 2024-06-19T02:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-reveals-new-phase-1-trial-data-for-kt-333-patsnap 2024-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-therapeutics-reveals-new-phase-1-trial-data-for-kt-333-patsnap 2024-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-report-from-the-children-s-oncology-group-new-agents 2024-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-report-from-the-children-s-oncology-group-new-agents 2024-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-extends-review-timeline-for-regenxbio-s-hunter-syndrome-gene-therapy-rgx-121 2024-06-18T07:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-extends-review-timeline-for-regenxbio-s-hunter-syndrome-gene-therapy-rgx-121 2024-06-18T07:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/cll-patients-prioritize-pfs-benefits-in-treatment-choices-survey-reveals 2024-06-18T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cll-patients-prioritize-pfs-benefits-in-treatment-choices-survey-reveals 2024-06-18T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-nav1-8-inhibitors-lead-wave-of-non-opioid-pain-treatments-as-industry-tackles-opioid-crisis 2024-06-18T04:41:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-nav1-8-inhibitors-lead-wave-of-non-opioid-pain-treatments-as-industry-tackles-opioid-crisis 2024-06-18T04:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-ventana-dp-200-digital-pathology-platform-for-clinical-diagnosis 2024-06-18T01:28:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-roche-s-ventana-dp-200-digital-pathology-platform-for-clinical-diagnosis 2024-06-18T01:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-submits-new-drug-application-to-fda-for-sebetralstat-as-first-oral-on-demand-treatment-for-hereditary-angioedema 2024-06-18T00:06:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-submits-new-drug-application-to-fda-for-sebetralstat-as-first-oral-on-demand-treatment-for-hereditary-angioedema 2024-06-18T00:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-presents-real-world-data-on-daybuetm-trofinetide-for-rett-syndrome 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-presents-real-world-data-on-daybuetm-trofinetide-for-rett-syndrome 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-in-calgary 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-in-calgary 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-skyrizi-r-risankizumab-rzaa-for-ulcerative-colitis 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-skyrizi-r-risankizumab-rzaa-for-ulcerative-colitis 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-bla-to-fda-for-lung-cancer-drug 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-bla-to-fda-for-lung-cancer-drug 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/three-rsv-vaccines-now-available-for-older-adults-as-fda-approves-moderna-s-mresvia 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-rsv-vaccines-now-available-for-older-adults-as-fda-approves-moderna-s-mresvia 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-in-2024-a-preview-of-trials-planned-to-initiate 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-in-2024-a-preview-of-trials-planned-to-initiate 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cerevel-therapeutics-advances-emraclidine-development-for-alzheimer-s-related-dementia-and-psychosis 2024-06-17T21:52:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerevel-therapeutics-advances-emraclidine-development-for-alzheimer-s-related-dementia-and-psychosis 2024-06-17T21:52:12+00:00 weekly 0.7 https://trial.medpath.com/news/zanubrutinib-combination-therapies-show-promise-in-high-risk-cll-sll-treatment 2024-06-17T20:09:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zanubrutinib-combination-therapies-show-promise-in-high-risk-cll-sll-treatment 2024-06-17T20:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-merck-s-capvaxive-first-21-serotype-pneumococcal-vaccine-designed-specifically-for-adults 2024-06-17T17:29:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-merck-s-capvaxive-first-21-serotype-pneumococcal-vaccine-designed-specifically-for-adults 2024-06-17T17:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-lynozyfic-receives-fda-approval-for-multiple-myeloma-with-70-response-rate 2024-06-17T08:32:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-s-lynozyfic-receives-fda-approval-for-multiple-myeloma-with-70-response-rate 2024-06-17T08:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-advances-development-program-for-hepatocellular-carcinoma-treatment 2024-06-17T07:59:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-keytruda-advances-development-program-for-hepatocellular-carcinoma-treatment 2024-06-17T07:59:02+00:00 weekly 0.7 https://trial.medpath.com/news/pharmamar-s-trabectedin-expands-development-portfolio-with-multiple-cancer-indications 2024-06-17T07:42:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmamar-s-trabectedin-expands-development-portfolio-with-multiple-cancer-indications 2024-06-17T07:42:59+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-bevacizumab-under-evaluation-for-endometrial-cancer-treatment 2024-06-17T07:41:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-bevacizumab-under-evaluation-for-endometrial-cancer-treatment 2024-06-17T07:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/argenx-to-unveil-vision-2030-and-share-updates-on-clinical-pipeline-at-r-d-day 2024-06-17T05:06:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/argenx-to-unveil-vision-2030-and-share-updates-on-clinical-pipeline-at-r-d-day 2024-06-17T05:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-shows-promising-results-in-lupus-and-autoimmune-diseases-at-eular-conference 2024-06-17T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promising-results-in-lupus-and-autoimmune-diseases-at-eular-conference 2024-06-17T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mendus-reports-promising-long-term-survival-data-for-vididencel-in-acute-myeloid-leukemia 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mendus-reports-promising-long-term-survival-data-for-vididencel-in-acute-myeloid-leukemia 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kite-s-yescarta-shows-superior-manufacturing-success-and-t-cell-performance-in-second-line-treatment-of-large-b-cell-lymphoma 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kite-s-yescarta-shows-superior-manufacturing-success-and-t-cell-performance-in-second-line-treatment-of-large-b-cell-lymphoma 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/avicursen-by-percheron-therapeutics-for-duchenne-muscular-dystrophy 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avicursen-by-percheron-therapeutics-for-duchenne-muscular-dystrophy 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/calquence-plus-chemoimmunotherapy-shows-27-reduction-in-disease-progression-risk-for-untreated-mantle-cell-lymphoma 2024-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calquence-plus-chemoimmunotherapy-shows-27-reduction-in-disease-progression-risk-for-untreated-mantle-cell-lymphoma 2024-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nih-s-novel-five-drug-combination-shows-promise-for-relapsed-aggressive-b-cell-lymphoma 2024-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-s-novel-five-drug-combination-shows-promise-for-relapsed-aggressive-b-cell-lymphoma 2024-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-s-car-t-therapy-shows-100-response-rate-in-high-risk-newly-diagnosed-multiple-myeloma-patients 2024-06-15T10:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iaso-bio-s-car-t-therapy-shows-100-response-rate-in-high-risk-newly-diagnosed-multiple-myeloma-patients 2024-06-15T10:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-columvi-demonstrates-41-reduction-in-death-risk-in-phase-iii-dlbcl-trial 2024-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-columvi-demonstrates-41-reduction-in-death-risk-in-phase-iii-dlbcl-trial 2024-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/disitamab-vedotin-plus-toripalimab-shows-early-efficacy-in-her2-positive-mibc 2024-06-14T19:05:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disitamab-vedotin-plus-toripalimab-shows-early-efficacy-in-her2-positive-mibc 2024-06-14T19:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/liso-cel-car-t-therapy-shows-promising-results-across-multiple-lymphoma-subtypes 2024-06-14T18:03:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liso-cel-car-t-therapy-shows-promising-results-across-multiple-lymphoma-subtypes 2024-06-14T18:03:33+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-presents-positive-clinical-data-across-portfolio 2024-06-14T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disc-medicine-presents-positive-clinical-data-across-portfolio 2024-06-14T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-blinatumomab-for-cd19-b-all-in-the 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-blinatumomab-for-cd19-b-all-in-the 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blood-stage-malaria-vaccine-candidate-rh5-1-matrix-m-trial-in-tanzania 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-stage-malaria-vaccine-candidate-rh5-1-matrix-m-trial-in-tanzania 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lixte-biotechnology-inks-deal-for-cancer-drug-trial 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lixte-biotechnology-inks-deal-for-cancer-drug-trial 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/deadline-approaching-for-transitioning-clinical-trials-from-ctd-to-ctr 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deadline-approaching-for-transitioning-clinical-trials-from-ctd-to-ctr 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-camrelizumab-an-anti-pd-1-antibody-plus-chemotherapy-or 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-camrelizumab-an-anti-pd-1-antibody-plus-chemotherapy-or 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ugn-102-demonstrates-long-term-durability-in-nmibc 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ugn-102-demonstrates-long-term-durability-in-nmibc 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-phase-iii-dmd-gene-therapy-study-misses-goal-pfizer-nyse-pfe-capricor-therapeutics-nasdaq-capr-benzinga 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-phase-iii-dmd-gene-therapy-study-misses-goal-pfizer-nyse-pfe-capricor-therapeutics-nasdaq-capr-benzinga 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/why-fda-panel-rejected-mdma-therapy-and-whats-next-for-psychedelic-medicine 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-fda-panel-rejected-mdma-therapy-and-whats-next-for-psychedelic-medicine 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-advances-phase-iii-trial-for-keytruda-biosimilar-fyb206-in-non-small-cell-lung-cancer 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formycon-advances-phase-iii-trial-for-keytruda-biosimilar-fyb206-in-non-small-cell-lung-cancer 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-axess-restorative-conduit-to-be-studied-in-fda-ide-pivotal-trial 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-axess-restorative-conduit-to-be-studied-in-fda-ide-pivotal-trial 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharmas-promising-trial-results-and-fda-progress-tipranks-com 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-pharmas-promising-trial-results-and-fda-progress-tipranks-com 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-holds-steady-promising-ugn-102-results-balanced-with-market-caution-markets-insider 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-pharma-holds-steady-promising-ugn-102-results-balanced-with-market-caution-markets-insider 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-oac-therapy-for-myotonic-dystrophy-type-1 2024-06-12T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-oac-therapy-for-myotonic-dystrophy-type-1 2024-06-12T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/swimming-microrobots-deliver-cancer-fighting-drugs-to-metastatic-lung-tumors-in-mice 2024-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/swimming-microrobots-deliver-cancer-fighting-drugs-to-metastatic-lung-tumors-in-mice 2024-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-confirms-efficacy-and-safety-of-antibody-drug-conjugates-in-advanced-urothelial-carcinoma-treatment 2024-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-confirms-efficacy-and-safety-of-antibody-drug-conjugates-in-advanced-urothelial-carcinoma-treatment 2024-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-2-results-for-setrusumab-in-osteogenesis-imperfecta-treatment 2024-06-11T21:47:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-2-results-for-setrusumab-in-osteogenesis-imperfecta-treatment 2024-06-11T21:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments 2024-06-11T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments 2024-06-11T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-concludes-subject-enrolment-in-dry-eye-disease-trial 2024-06-11T12:58:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-concludes-subject-enrolment-in-dry-eye-disease-trial 2024-06-11T12:58:37+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday 2024-06-11T12:56:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday 2024-06-11T12:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-wins-fda-approval-for-rsv-vaccine 2024-06-11T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-wins-fda-approval-for-rsv-vaccine 2024-06-11T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-rsv-vaccine-arexvy-gets-fda-nod-for-adults-50-59-years 2024-06-11T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-rsv-vaccine-arexvy-gets-fda-nod-for-adults-50-59-years 2024-06-11T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-hormonal-gel-shows-promise-for-male-birth-control 2024-06-11T12:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-of-hormonal-gel-shows-promise-for-male-birth-control 2024-06-11T12:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/three-promising-drugs-for-treating-alzheimer-s-disease-bring-fresh-hope 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-promising-drugs-for-treating-alzheimer-s-disease-bring-fresh-hope 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moonlake-immunotherapeutics-initiates-phase-3-vela-program-for-sonelokimab-in-hidradenitis-suppurativa-treatment 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moonlake-immunotherapeutics-initiates-phase-3-vela-program-for-sonelokimab-in-hidradenitis-suppurativa-treatment 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-impact-of-cholesterol-changes-on-cardiovascular-disease-risk 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-impact-of-cholesterol-changes-on-cardiovascular-disease-risk 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upadacitinib-outperforms-dupilumab-in-landmark-level-up-trial-for-moderate-to-severe-atopic-dermatitis 2024-06-10T21:35:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upadacitinib-outperforms-dupilumab-in-landmark-level-up-trial-for-moderate-to-severe-atopic-dermatitis 2024-06-10T21:35:51+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-combination-flu-covid-vaccine-shows-superior-immune-response-in-phase-3-trial 2024-06-10T16:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-s-combination-flu-covid-vaccine-shows-superior-immune-response-in-phase-3-trial 2024-06-10T16:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-s-slow-adoption-challenges-and-progress-in-alzheimer-s-treatment 2024-06-10T09:00:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leqembi-s-slow-adoption-challenges-and-progress-in-alzheimer-s-treatment 2024-06-10T09:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-receives-irb-approval-for-phase-iia-pancreatic-cancer-trial-of-namodenoson 2024-06-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-receives-irb-approval-for-phase-iia-pancreatic-cancer-trial-of-namodenoson 2024-06-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-radiographic-evaluation-of-mineral-trioxide-aggregate-and-human-amniotic-membrane-in-primary-molar-teeth 2024-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-and-radiographic-evaluation-of-mineral-trioxide-aggregate-and-human-amniotic-membrane-in-primary-molar-teeth 2024-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-s-iqirvo-receives-u-s-fda-accelerated-approval-for-primary-biliary-cholangitis-treatment 2024-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-s-iqirvo-receives-u-s-fda-accelerated-approval-for-primary-biliary-cholangitis-treatment 2024-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-eisai-s-filing-of-leqembi-r-for-alzheimer-s-disease-treatment 2024-06-09T23:37:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-eisai-s-filing-of-leqembi-r-for-alzheimer-s-disease-treatment 2024-06-09T23:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/concierge-medicine-market-set-to-reach-10-9-billion-by-2032-amid-growing-healthcare-disparities 2024-06-07T02:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/concierge-medicine-market-set-to-reach-10-9-billion-by-2032-amid-growing-healthcare-disparities 2024-06-07T02:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/this-pharma-stock-dropped-60-premarket-as-fda-halted-diabetes-drug-trials-biomea-fusion-nasdaq-bmea-benzinga 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-pharma-stock-dropped-60-premarket-as-fda-halted-diabetes-drug-trials-biomea-fusion-nasdaq-bmea-benzinga 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-shares-rise-after-fda-s-telomerase-inhibitor 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-shares-rise-after-fda-s-telomerase-inhibitor 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/petros-pharmaceuticals-completes-ai-integrated-study-for 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/petros-pharmaceuticals-completes-ai-integrated-study-for 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-abbv-ovarian-cancer-therapy-meets-study-goal 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-abbv-ovarian-cancer-therapy-meets-study-goal 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rytelotm-imetelstat-for-lower-risk-mds-with-transfusion-dependent-anemia 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-rytelotm-imetelstat-for-lower-risk-mds-with-transfusion-dependent-anemia 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dual-agonist-drug-survodutide-shows-promise-in-phase-2-trial-for-fatty-liver-disease-treatment 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dual-agonist-drug-survodutide-shows-promise-in-phase-2-trial-for-fatty-liver-disease-treatment 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-geron-s-treatment-for-lower-risk-mds-blood-cancer-by-investing-com 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-geron-s-treatment-for-lower-risk-mds-blood-cancer-by-investing-com 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abu-dhabi-health-department-and-novartis-partner-to-advance-genomics-research-and-radioligand-therapy 2024-06-06T22:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abu-dhabi-health-department-and-novartis-partner-to-advance-genomics-research-and-radioligand-therapy 2024-06-06T22:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rescinds-marketing-ban-on-juul-vaping-products-returns-applications-to-review-status 2024-06-06T17:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rescinds-marketing-ban-on-juul-vaping-products-returns-applications-to-review-status 2024-06-06T17:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-oncology-therapeutics-announces-first-patient-dosed-with-bbo-8520-in-the-onkoras-101-trial-for-krasg12c-nsclc 2024-06-06T15:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-oncology-therapeutics-announces-first-patient-dosed-with-bbo-8520-in-the-onkoras-101-trial-for-krasg12c-nsclc 2024-06-06T15:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-year-to-date-achievements-and-highlights 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-year-to-date-achievements-and-highlights 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilcare-and-shionogi-form-eur400-million-partnership-to-develop-novel-hearing-loss-treatments 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilcare-and-shionogi-form-eur400-million-partnership-to-develop-novel-hearing-loss-treatments 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-to-present-alfapump-r-safety-and-quality-of-life-data-at-easl-congress-2024 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-to-present-alfapump-r-safety-and-quality-of-life-data-at-easl-congress-2024 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-panel-unanimously-recommends-jn-1-targeted-covid-19-vaccines-for-fall-2024 2024-06-05T21:02:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advisory-panel-unanimously-recommends-jn-1-targeted-covid-19-vaccines-for-fall-2024 2024-06-05T21:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/bilateral-gene-therapy-restores-hearing-in-both-ears-for-children-with-inherited-deafness 2024-06-05T09:00:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bilateral-gene-therapy-restores-hearing-in-both-ears-for-children-with-inherited-deafness 2024-06-05T09:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/inhibikase-therapeutics-completes-enrollment-in-phase-2-trial-for-parkinson-s-disease-treatment 2024-06-05T08:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inhibikase-therapeutics-completes-enrollment-in-phase-2-trial-for-parkinson-s-disease-treatment 2024-06-05T08:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-expand-pain-portfolio-with-siteone-acquisition 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-to-expand-pain-portfolio-with-siteone-acquisition 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/streamlining-clinical-trials-in-finland-s-unique-environment 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/streamlining-clinical-trials-in-finland-s-unique-environment 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-announces-clinical-trial-collaboration-with-pfizer-to-evaluate-atirmociclib-in-combination-with-rly-2608 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relay-therapeutics-announces-clinical-trial-collaboration-with-pfizer-to-evaluate-atirmociclib-in-combination-with-rly-2608 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-positive-16-week-data-from-its-global-phase-2b-3-trial-of-izokibep-in-psoriatic-arthritis-to-be-shared-during-late-breaking-oral-presentation-at-eular-2024-biospace 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-announces-positive-16-week-data-from-its-global-phase-2b-3-trial-of-izokibep-in-psoriatic-arthritis-to-be-shared-during-late-breaking-oral-presentation-at-eular-2024-biospace 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-s-elafibranor-demonstrates-sustained-efficacy-in-primary-biliary-cholangitis-phase-iii-trial 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-s-elafibranor-demonstrates-sustained-efficacy-in-primary-biliary-cholangitis-phase-iii-trial 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asco24-j-j-innovative-medicine-touts-positive-multiple-myeloma-drug-data 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asco24-j-j-innovative-medicine-touts-positive-multiple-myeloma-drug-data 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-weight-loss-drugs-like-ozempic-show-promising-cancer-prevention-benefits 2024-06-04T17:27:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-weight-loss-drugs-like-ozempic-show-promising-cancer-prevention-benefits 2024-06-04T17:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-s-tak-861-shows-promising-results-in-phase-2b-trial-for-narcolepsy-type-1 2024-06-04T13:01:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/takeda-s-tak-861-shows-promising-results-in-phase-2b-trial-for-narcolepsy-type-1 2024-06-04T13:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-clinical-trials-begin-for-twice-yearly-hiv-prevention-injection 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-clinical-trials-begin-for-twice-yearly-hiv-prevention-injection 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/carsgen-s-satri-cel-shows-promise-in-phase-1-trial-for-gastrointestinal-cancers 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carsgen-s-satri-cel-shows-promise-in-phase-1-trial-for-gastrointestinal-cancers 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ad109-advances-to-phase-iii-trials-as-first-oral-therapy-for-obstructive-sleep-apnea 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ad109-advances-to-phase-iii-trials-as-first-oral-therapy-for-obstructive-sleep-apnea 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/capricor-therapeutics-announces-positive-3-year-efficacy 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capricor-therapeutics-announces-positive-3-year-efficacy 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glycomimetics-announces-comprehensive-results-from-pivotal-phase-3-study-of-uproleselan-in-relapsed-refractory-r-r-acute-myeloid-leukemia-aml 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glycomimetics-announces-comprehensive-results-from-pivotal-phase-3-study-of-uproleselan-in-relapsed-refractory-r-r-acute-myeloid-leukemia-aml 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-highlights-phase-3-sarclisa-data-in-multiple-myeloma-treatment 2024-06-03T20:00:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-highlights-phase-3-sarclisa-data-in-multiple-myeloma-treatment 2024-06-03T20:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-data-shows-enhertu-reduces-breast-cancer-progression-risk-by-38-as-access-remains-denied-in-england 2024-06-03T16:51:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trial-data-shows-enhertu-reduces-breast-cancer-progression-risk-by-38-as-access-remains-denied-in-england 2024-06-03T16:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/crinetics-reports-promising-results-for-atumelnant-in-treating-cah-and-acth-dependent-cushings-syndrome 2024-06-03T16:06:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crinetics-reports-promising-results-for-atumelnant-in-treating-cah-and-acth-dependent-cushings-syndrome 2024-06-03T16:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-antibodies-show-promise-in-multiple-myeloma-treatment-across-different-patient-populations 2024-06-03T15:18:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bispecific-antibodies-show-promise-in-multiple-myeloma-treatment-across-different-patient-populations 2024-06-03T15:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/structure-s-obesity-pill-shows-promising-weight-loss-results-in-study 2024-06-03T12:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/structure-s-obesity-pill-shows-promising-weight-loss-results-in-study 2024-06-03T12:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-shows-mirikizumab-s-efficacy-in-crohn-s-disease-treatment 2024-06-03T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-data-shows-mirikizumab-s-efficacy-in-crohn-s-disease-treatment 2024-06-03T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-launches-qiastat-dx-gastrointestinal-panel-2-in-the-u-s-for-improved-gi-infection-diagnosis 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-launches-qiastat-dx-gastrointestinal-panel-2-in-the-u-s-for-improved-gi-infection-diagnosis 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-advances-personalized-cancer-vaccine-tg4050-to-phase-ii-trial-in-head-and-neck-cancer 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-advances-personalized-cancer-vaccine-tg4050-to-phase-ii-trial-in-head-and-neck-cancer 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mid-stage-trial-failure-for-sanofi-and-denali-s-als-drug 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mid-stage-trial-failure-for-sanofi-and-denali-s-als-drug 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eledon-s-tegoprubart-shows-superior-kidney-function-preservation-in-phase-1b-transplant-trial 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eledon-s-tegoprubart-shows-superior-kidney-function-preservation-in-phase-1b-transplant-trial 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tagrisso-demonstrates-84-reduction-in-disease-progression-risk-for-egfr-mutated-stage-3-nsclc 2024-06-02T12:00:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tagrisso-demonstrates-84-reduction-in-disease-progression-risk-for-egfr-mutated-stage-3-nsclc 2024-06-02T12:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/2024-san-antonio-breast-cancer-symposium 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-san-antonio-breast-cancer-symposium 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/caribou-biosciences-reports-positive-clinical-data-from-cb-010-antler-phase-1-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caribou-biosciences-reports-positive-clinical-data-from-cb-010-antler-phase-1-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bio-thera-s-bat8006-shows-promising-37-response-rate-in-platinum-resistant-ovarian-cancer-phase-i-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-thera-s-bat8006-shows-promising-37-response-rate-in-platinum-resistant-ovarian-cancer-phase-i-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/newron-myung-collaborate-for-evenamide-development-in-south-korea 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newron-myung-collaborate-for-evenamide-development-in-south-korea 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-camrelizumab-plus-rivoceranib-maintains-survival-onclive 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-camrelizumab-plus-rivoceranib-maintains-survival-onclive 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-shows-promise-in-platinum-resistant-ovarian-cancer-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-keytruda-shows-promise-in-platinum-resistant-ovarian-cancer-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chime-mabgeek-achieve-phase-iii-milestone-with-mg-k10 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chime-mabgeek-achieve-phase-iii-milestone-with-mg-k10 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-launches-in-austria-and-germany-as-first-anti-amyloid-alzheimer-s-therapy-in-eu 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leqembi-launches-in-austria-and-germany-as-first-anti-amyloid-alzheimer-s-therapy-in-eu 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-launches-first-ustekinumab-biosimilar-autoinjector-in-europe-with-pyzchiva 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sandoz-launches-first-ustekinumab-biosimilar-autoinjector-in-europe-with-pyzchiva 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-s-crispr-gene-therapy-shows-potential-as-functional-cure-for-hereditary-angioedema-in-long-term-study 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-s-crispr-gene-therapy-shows-potential-as-functional-cure-for-hereditary-angioedema-in-long-term-study 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-reports-77-complete-response-rate-for-padeliporfin-vtp-in-low-grade-upper-tract-urothelial-cancer 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-biotech-reports-77-complete-response-rate-for-padeliporfin-vtp-in-low-grade-upper-tract-urothelial-cancer 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ultra-sensitive-blood-test-predicts-breast-cancer-recurrence-up-to-41-months-before-clinical-symptoms 2024-06-01T23:01:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultra-sensitive-blood-test-predicts-breast-cancer-recurrence-up-to-41-months-before-clinical-symptoms 2024-06-01T23:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-amivantamab-demonstrates-superior-outcomes-over-iv-administration-in-egfr-mutated-nsclc 2024-06-01T18:55:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-amivantamab-demonstrates-superior-outcomes-over-iv-administration-in-egfr-mutated-nsclc 2024-06-01T18:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/amivantamab-plus-lazertinib-improves-pfs-irrespective-of 2024-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amivantamab-plus-lazertinib-improves-pfs-irrespective-of 2024-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-s-gohibic-vilobelimab-selected-for-first-barda-sponsored-clinical-trial 2024-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflarx-s-gohibic-vilobelimab-selected-for-first-barda-sponsored-clinical-trial 2024-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asco-2024-highlights-breakthroughs-in-cancer-treatment 2024-05-31T15:08:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asco-2024-highlights-breakthroughs-in-cancer-treatment 2024-05-31T15:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-fda-acceptance-of-resubmission-of-nda-for-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-05-31T02:05:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-receives-fda-acceptance-of-resubmission-of-nda-for-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-05-31T02:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-r-phase-iii-data-first-to-show-superior-efficacy-with-a-favorable-safety-and-tolerability-profile-vs-standard-of-care-tkis-in-adults-with-newly-diagnosed-cml-novartis 2024-05-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-r-phase-iii-data-first-to-show-superior-efficacy-with-a-favorable-safety-and-tolerability-profile-vs-standard-of-care-tkis-in-adults-with-newly-diagnosed-cml-novartis 2024-05-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strand-therapeutics-doses-first-patient-with-programmable-mrna-cancer-therapy-stx-001-in-phase-1-trial 2024-05-30T11:36:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strand-therapeutics-doses-first-patient-with-programmable-mrna-cancer-therapy-stx-001-in-phase-1-trial 2024-05-30T11:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-regenerative-medicine-advanced-therapy-designation-to-bemdaneprocel-for-parkinsons-disease 2024-05-30T09:00:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-regenerative-medicine-advanced-therapy-designation-to-bemdaneprocel-for-parkinsons-disease 2024-05-30T09:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-and-trends-in-anti-obesity-drug-development-for-2024 2024-05-30T06:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-and-trends-in-anti-obesity-drug-development-for-2024 2024-05-30T06:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-acknowledges-astellas-resubmission-of-biologics-license-application-for-zolbetuximab-and-sets-new-action-date 2024-05-30T05:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-acknowledges-astellas-resubmission-of-biologics-license-application-for-zolbetuximab-and-sets-new-action-date 2024-05-30T05:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-101-shows-promise-as-first-antidepressant-to-reduce-suicidality-in-bipolar-depression 2024-05-29T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrx-101-shows-promise-as-first-antidepressant-to-reduce-suicidality-in-bipolar-depression 2024-05-29T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-advances-in-clinical-trial-for-genetic-ftd-treatment 2024-05-29T09:00:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/passage-bio-advances-in-clinical-trial-for-genetic-ftd-treatment 2024-05-29T09:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/cellectar-biosciences-partners-with-city-of-hope-cancer-center-for-iopofosine-clinical-development 2024-05-29T06:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellectar-biosciences-partners-with-city-of-hope-cancer-center-for-iopofosine-clinical-development 2024-05-29T06:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-cardamyst 2024-05-29T02:05:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/milestone-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-cardamyst 2024-05-29T02:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-roches-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation 2024-05-29T02:05:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-roches-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation 2024-05-29T02:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-lonigutamab-phase-1-2-proof-of-concept-data-to-be-shared-during-late-breaking-oral-presentation-at-endo-2024-marketscreener 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-announces-lonigutamab-phase-1-2-proof-of-concept-data-to-be-shared-during-late-breaking-oral-presentation-at-endo-2024-marketscreener 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/extended-daratumumab-krd-therapy-achieves-85-three-year-pfs-in-newly-diagnosed-multiple-myeloma-without-transplant 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/extended-daratumumab-krd-therapy-achieves-85-three-year-pfs-in-newly-diagnosed-multiple-myeloma-without-transplant 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-landgren-on-the-utility-of-mrd-as-an-end-point-in 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-landgren-on-the-utility-of-mrd-as-an-end-point-in 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-develops-first-in-class-broad-spectrum-antiviral-agent-nv-387 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-develops-first-in-class-broad-spectrum-antiviral-agent-nv-387 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-medicine-and-pmv-pharma-partner-to-develop-companion-diagnostic-for-rezatapopt 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foundation-medicine-and-pmv-pharma-partner-to-develop-companion-diagnostic-for-rezatapopt 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cdc-clinical-guidelines-on-the-use-of-doxycycline 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cdc-clinical-guidelines-on-the-use-of-doxycycline 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spineart-receives-fda-510-k-clearance-for-scarlet-ac-ti-anterior-cervical-cage-with-advanced-ti-life-technology 2024-05-28T15:40:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spineart-receives-fda-510-k-clearance-for-scarlet-ac-ti-anterior-cervical-cage-with-advanced-ti-life-technology 2024-05-28T15:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-krazati-plus-cetuximab-for-kras-g12c-mutated-colorectal-cancer 2024-05-28T14:55:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-krazati-plus-cetuximab-for-kras-g12c-mutated-colorectal-cancer 2024-05-28T14:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-expands-portfolio-with-1-25b-acquisition-of-skin-disease-medicine 2024-05-28T10:54:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-expands-portfolio-with-1-25b-acquisition-of-skin-disease-medicine 2024-05-28T10:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/resminostat-s-approval-by-the-ema-and-the-fda-mhra-and-more-how 2024-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/resminostat-s-approval-by-the-ema-and-the-fda-mhra-and-more-how 2024-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rosacea-pipeline-analysis-2024-insights-into-therapeutics-development 2024-05-27T18:55:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rosacea-pipeline-analysis-2024-insights-into-therapeutics-development 2024-05-27T18:55:52+00:00 weekly 0.7 https://trial.medpath.com/news/remegen-s-telitacicept-receives-priority-review-for-myasthenia-gravis-treatment-following-successful-phase-iii-trial 2024-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remegen-s-telitacicept-receives-priority-review-for-myasthenia-gravis-treatment-following-successful-phase-iii-trial 2024-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pneumagen-s-neumifil-shows-promising-results-in-phase-2-influenza-prevention-trial 2024-05-24T16:59:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pneumagen-s-neumifil-shows-promising-results-in-phase-2-influenza-prevention-trial 2024-05-24T16:59:01+00:00 weekly 0.7 https://trial.medpath.com/news/ema-validates-marketing-applications-for-hlx14-denosumab-biosimilar-in-osteoporosis-treatment 2024-05-24T10:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-validates-marketing-applications-for-hlx14-denosumab-biosimilar-in-osteoporosis-treatment 2024-05-24T10:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-drug-discovery-accelerates-with-new-academic-alliance-targeting-protein-kinases 2024-05-23T14:29:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-driven-drug-discovery-accelerates-with-new-academic-alliance-targeting-protein-kinases 2024-05-23T14:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-vcn-01-for-metastatic-pancreatic-cancer-treatment 2024-05-23T14:27:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-vcn-01-for-metastatic-pancreatic-cancer-treatment 2024-05-23T14:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/eyp-1901-shows-promise-in-reducing-treatment-burden-for-wet-amd-patients-in-phase-2-davio-2-trial 2024-05-23T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyp-1901-shows-promise-in-reducing-treatment-burden-for-wet-amd-patients-in-phase-2-davio-2-trial 2024-05-23T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-to-present-latest-hepatitis-delta-and-b-data-at-easl-congress-2024 2024-05-22T12:16:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-to-present-latest-hepatitis-delta-and-b-data-at-easl-congress-2024 2024-05-22T12:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-expands-into-immunology-with-acquisition-of-hi-bio 2024-05-22T11:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-expands-into-immunology-with-acquisition-of-hi-bio 2024-05-22T11:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/home-immix-biopharma-inc 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/home-immix-biopharma-inc 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/can-ai-predict-the-development-of-autoimmune-diseases 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-ai-predict-the-development-of-autoimmune-diseases 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-positive-fda-meeting-outcome-for-alfapump-pma-application 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-announces-positive-fda-meeting-outcome-for-alfapump-pma-application 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-efficacy-and-safety-of-sglt2-inhibitors-in-type-2-diabetes-management 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-highlights-efficacy-and-safety-of-sglt2-inhibitors-in-type-2-diabetes-management 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-path-for-cingulate-s-ctx-1301-adhd-treatment-nda-submission 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-path-for-cingulate-s-ctx-1301-adhd-treatment-nda-submission 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/henlius-to-present-latest-clinical-data-of-hlx22-at-2024-esmo-gastrointestinal-cancers-congress 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/henlius-to-present-latest-clinical-data-of-hlx22-at-2024-esmo-gastrointestinal-cancers-congress 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atara-biotherapeutics-submits-tabelecleucel-tab-cel-r-biologics-license-application-for-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-with-u-s-fda 2024-05-20T23:05:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atara-biotherapeutics-submits-tabelecleucel-tab-cel-r-biologics-license-application-for-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-with-u-s-fda 2024-05-20T23:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/spinogenix-receives-fda-orphan-drug-designation-for-spg601-to-treat-fragile-x-syndrome 2024-05-20T13:51:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spinogenix-receives-fda-orphan-drug-designation-for-spg601-to-treat-fragile-x-syndrome 2024-05-20T13:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-vaccine-breakthrough-new-candidate-successfully-generates-broadly-neutralizing-antibodies 2024-05-20T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hiv-vaccine-breakthrough-new-candidate-successfully-generates-broadly-neutralizing-antibodies 2024-05-20T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neuralink-gets-fda-approval-for-second-brain-implant-patient-wsj 2024-05-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuralink-gets-fda-approval-for-second-brain-implant-patient-wsj 2024-05-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anokion-announces-promising-clinical-data-for-kan-101-in-celiac-disease-treatment 2024-05-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anokion-announces-promising-clinical-data-for-kan-101-in-celiac-disease-treatment 2024-05-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-non-hormonal-therapy-shows-promise-in-reducing-hot-flashes-in-phase-iii-trials 2024-05-17T11:13:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-s-non-hormonal-therapy-shows-promise-in-reducing-hot-flashes-in-phase-iii-trials 2024-05-17T11:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/progress-in-sclc-from-deadly-to-cure 2024-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/progress-in-sclc-from-deadly-to-cure 2024-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maternal-vaccine-trials-face-critical-challenges-only-6-of-late-stage-studies-include-pregnant-women 2024-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maternal-vaccine-trials-face-critical-challenges-only-6-of-late-stage-studies-include-pregnant-women 2024-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-once-weekly-insulin-efsitora-demonstrates-non-inferior-efficacy-in-phase-3-trials-for-type-2-diabetes 2024-05-16T17:55:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-once-weekly-insulin-efsitora-demonstrates-non-inferior-efficacy-in-phase-3-trials-for-type-2-diabetes 2024-05-16T17:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/south-rampart-pharma-s-srp-001-shows-promise-as-non-opioid-pain-treatment-in-phase-1-trial 2024-05-16T10:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-rampart-pharma-s-srp-001-shows-promise-as-non-opioid-pain-treatment-in-phase-1-trial 2024-05-16T10:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/investors-launch-400m-hercules-startup-to-develop-novel-glp-1-therapies-for-obesity-and-diabetes 2024-05-16T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investors-launch-400m-hercules-startup-to-develop-novel-glp-1-therapies-for-obesity-and-diabetes 2024-05-16T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-amgen-s-treatment-for-most-deadly-form-of-lung-cancer 2024-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-amgen-s-treatment-for-most-deadly-form-of-lung-cancer 2024-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lsu-health-new-orleans-develops-novel-non-addictive-painkiller-with-fda-fast-track-designation 2024-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lsu-health-new-orleans-develops-novel-non-addictive-painkiller-with-fda-fast-track-designation 2024-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/optilume-bph-catheter-system-preserves-sexual-function-while-treating-luts 2024-05-15T19:30:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optilume-bph-catheter-system-preserves-sexual-function-while-treating-luts 2024-05-15T19:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/south-korea-accelerates-drug-reimbursement-process-with-new-pilot-program 2024-05-15T11:22:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-korea-accelerates-drug-reimbursement-process-with-new-pilot-program 2024-05-15T11:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/pioneering-immunotherapy-approach-keeps-brain-cancer-at-bay-for-australian-doctor-who-helped-develop-it 2024-05-15T06:05:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pioneering-immunotherapy-approach-keeps-brain-cancer-at-bay-for-australian-doctor-who-helped-develop-it 2024-05-15T06:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/study-of-tecovirimat-for-human-mpox-virus-stomp 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-of-tecovirimat-for-human-mpox-virus-stomp 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blackstone-launches-uniquity-bio-with-300m-to-advance-anti-tslp-therapy-for-asthma-and-copd 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blackstone-launches-uniquity-bio-with-300m-to-advance-anti-tslp-therapy-for-asthma-and-copd 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-advances-ons-5010-toward-potential-first-approved-ophthalmic-bevacizumab-for-retinal-diseases 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outlook-therapeutics-advances-ons-5010-toward-potential-first-approved-ophthalmic-bevacizumab-for-retinal-diseases 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hpv-self-collection-for-cervical-cancer-screening-expanding-access-to-early-detection 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-hpv-self-collection-for-cervical-cancer-screening-expanding-access-to-early-detection 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-announces-global-offering-to-fund-microbiome-ecosystem-therapies-development 2024-05-14T16:01:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maat-pharma-announces-global-offering-to-fund-microbiome-ecosystem-therapies-development 2024-05-14T16:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-to-present-promising-rvu120-and-synthetic-lethality-data-at-major-oncology-conferences 2024-05-14T15:39:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ryvu-therapeutics-to-present-promising-rvu120-and-synthetic-lethality-data-at-major-oncology-conferences 2024-05-14T15:39:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ind-application-for-synkir-310-trial-in-relapsed-refractory-b-nhl 2024-05-14T13:29:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-ind-application-for-synkir-310-trial-in-relapsed-refractory-b-nhl 2024-05-14T13:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/xilio-therapeutics-advances-tumor-activated-immunotherapy-pipeline-with-phase-2-trial-of-xtx101-set-for-q3-2024 2024-05-14T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xilio-therapeutics-advances-tumor-activated-immunotherapy-pipeline-with-phase-2-trial-of-xtx101-set-for-q3-2024 2024-05-14T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-announces-extension-of-u-s-food-and-drug-administration-review-period-for-transcon-pth-for-adults-with-hypoparathyroidism 2024-05-14T01:05:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-announces-extension-of-u-s-food-and-drug-administration-review-period-for-transcon-pth-for-adults-with-hypoparathyroidism 2024-05-14T01:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/nyxoah-s-genio-system-shows-strong-results-in-dream-pivotal-study-for-obstructive-sleep-apnea-treatment 2024-05-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nyxoah-s-genio-system-shows-strong-results-in-dream-pivotal-study-for-obstructive-sleep-apnea-treatment 2024-05-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-ceo-discusses-nv-387-s-broad-spectrum 2024-05-13T15:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-ceo-discusses-nv-387-s-broad-spectrum 2024-05-13T15:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-snb-101-for-small-cell-lung-cancer-treatment 2024-05-13T14:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-snb-101-for-small-cell-lung-cancer-treatment 2024-05-13T14:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/sumitomo-pharma-announces-fda-acceptance-of-supplemental-new-drug 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sumitomo-pharma-announces-fda-acceptance-of-supplemental-new-drug 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-the-results-of-wegovys-longest-clinical-trial-yet-show-about-weight-loss-side-effects-and-heart-protection-cnn 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-the-results-of-wegovys-longest-clinical-trial-yet-show-about-weight-loss-side-effects-and-heart-protection-cnn 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/plant-virus-nanoparticles-show-broad-protection-against-metastatic-cancers-in-preclinical-studies 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plant-virus-nanoparticles-show-broad-protection-against-metastatic-cancers-in-preclinical-studies 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-reports-first-quarter-2024-financial-results-and-corporate-update 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-reports-first-quarter-2024-financial-results-and-corporate-update 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-announces-date-for-envision-data-new-long-term-jelmyto-durability-data-and-reports-2024-first-quarter-financial-results-and-business-highlights 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-pharma-announces-date-for-envision-data-new-long-term-jelmyto-durability-data-and-reports-2024-first-quarter-financial-results-and-business-highlights 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-clinical-trial-to-treat-depression-in-oxford-university-study 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-clinical-trial-to-treat-depression-in-oxford-university-study 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-phase-3-keyvibe-010-trial-evaluating-an 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-provides-update-on-phase-3-keyvibe-010-trial-evaluating-an 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kite-and-arcellx-prepare-to-launch-phase-iii-multiple-myeloma-trial 2024-05-12T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kite-and-arcellx-prepare-to-launch-phase-iii-multiple-myeloma-trial 2024-05-12T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/agenus-agen-q1-2024-earnings-call-transcript 2024-05-12T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agenus-agen-q1-2024-earnings-call-transcript 2024-05-12T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/surprise-eli-lilly-is-racing-toward-yet-another-blockbuster 2024-05-12T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/surprise-eli-lilly-is-racing-toward-yet-another-blockbuster 2024-05-12T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-inc-kymr-q1-2024-earnings-call-transcript-highlights 2024-05-12T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-therapeutics-inc-kymr-q1-2024-earnings-call-transcript-highlights 2024-05-12T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-dermatitis-focused-rapt-therapeutics-stock-on-thursday 2024-05-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-going-on-with-dermatitis-focused-rapt-therapeutics-stock-on-thursday 2024-05-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-inc-reports-q1-2024-earnings-a-detailed-financial-overview 2024-05-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapt-therapeutics-inc-reports-q1-2024-earnings-a-detailed-financial-overview 2024-05-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/fibrogen-inc-nasdaq-fgen-q1-2024-earnings-call-transcript 2024-05-12T13:01:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fibrogen-inc-nasdaq-fgen-q1-2024-earnings-call-transcript 2024-05-12T13:01:21+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-pharmaceuticals-incorporated-nasdaq-vrtx-q1-2024-earnings-call 2024-05-12T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-incorporated-nasdaq-vrtx-q1-2024-earnings-call 2024-05-12T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/q1-2024-axsome-therapeutics-inc-earnings-call 2024-05-12T12:29:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q1-2024-axsome-therapeutics-inc-earnings-call 2024-05-12T12:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study 2024-05-12T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study 2024-05-12T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-provides-business-updates-and-reports-first 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recursion-provides-business-updates-and-reports-first 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dll3-guided-therapies-show-promise-in-small-cell-lung-cancer-treatment 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dll3-guided-therapies-show-promise-in-small-cell-lung-cancer-treatment 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-piwei-peiyuan-prescription-in-treating-chronic-atrophic-gastritis 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-piwei-peiyuan-prescription-in-treating-chronic-atrophic-gastritis 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmather-receives-fda-goal-date-of-october-29-2024-for-priority-ketamine-anda-approval 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmather-receives-fda-goal-date-of-october-29-2024-for-priority-ketamine-anda-approval 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/reflections-on-the-new-fda-clinical-pharmacology-guidance-for-antibody-drug-conjugates 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reflections-on-the-new-fda-clinical-pharmacology-guidance-for-antibody-drug-conjugates 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-reports-first-quarter-2024-financial-results-and-operational-progress 2024-05-09T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-therapeutics-reports-first-quarter-2024-financial-results-and-operational-progress 2024-05-09T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-provides-business-update-and-highlights-key-upcoming-milestones 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-provides-business-update-and-highlights-key-upcoming-milestones 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/r3-vascular-secures-87-million-in-series-b-financing-and-appoints-new-ceo 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/r3-vascular-secures-87-million-in-series-b-financing-and-appoints-new-ceo 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/know-labs-to-present-clinical-research-at-the-2024-american-association-of-clinical-endocrinology-annual-meeting 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/know-labs-to-present-clinical-research-at-the-2024-american-association-of-clinical-endocrinology-annual-meeting 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/siren-biotechnology-partners-with-catalent-to-advance-aav-immuno-gene-therapies-for-cancer 2024-05-08T15:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/siren-biotechnology-partners-with-catalent-to-advance-aav-immuno-gene-therapies-for-cancer 2024-05-08T15:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-receives-fda-approval-for-confirmatory-study-of-multikine-in-head-and-neck-cancer-treatment 2024-05-08T13:16:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cel-sci-receives-fda-approval-for-confirmatory-study-of-multikine-in-head-and-neck-cancer-treatment 2024-05-08T13:16:06+00:00 weekly 0.7 https://trial.medpath.com/news/tivic-health-s-non-invasive-vagus-nerve-stimulation-shows-promising-results-in-clinical-trial 2024-05-08T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tivic-health-s-non-invasive-vagus-nerve-stimulation-shows-promising-results-in-clinical-trial 2024-05-08T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teva-and-medincell-announce-positive-phase-3-efficacy-results-for-tev-749-in-schizophrenia-treatment 2024-05-08T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-and-medincell-announce-positive-phase-3-efficacy-results-for-tev-749-in-schizophrenia-treatment 2024-05-08T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/arcturus-therapeutics-announces-first-quarter-2024-financial-update-and 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arcturus-therapeutics-announces-first-quarter-2024-financial-update-and 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-in-class-hiv-1-treatment 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-in-class-hiv-1-treatment 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/participants-of-pioneering-crispr-gene-editing-trial-see-vision 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/participants-of-pioneering-crispr-gene-editing-trial-see-vision 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-a-fib-history-cleared-by-fda-for-use-in-clinical-trials 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-s-a-fib-history-cleared-by-fda-for-use-in-clinical-trials 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-acquires-mariana-oncology-for-1-billion-to-strengthen-radioligand-therapy-pipeline 2024-05-07T10:47:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-acquires-mariana-oncology-for-1-billion-to-strengthen-radioligand-therapy-pipeline 2024-05-07T10:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/d3s-001-shows-superior-kras-g12c-inhibition-with-rapid-target-engagement-and-promising-clinical-activity 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d3s-001-shows-superior-kras-g12c-inhibition-with-rapid-target-engagement-and-promising-clinical-activity 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/denali-therapeutics-reports-first-quarter-2024-financial 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/denali-therapeutics-reports-first-quarter-2024-financial 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-provides-business-and-clinical-update-and-reports-first-quarter-2024-financial-results 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-provides-business-and-clinical-update-and-reports-first-quarter-2024-financial-results 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-secures-final-china-patent-for-synthetic-anti-infectives-completing-global-protection-until-2035 2024-05-06T23:47:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-secures-final-china-patent-for-synthetic-anti-infectives-completing-global-protection-until-2035 2024-05-06T23:47:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-colosense-first-rna-based-noninvasive-colorectal-cancer-screening-test 2024-05-06T14:50:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-colosense-first-rna-based-noninvasive-colorectal-cancer-screening-test 2024-05-06T14:50:45+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-inc-advances-psychedelic-treatments-for-mental-health 2024-05-06T13:08:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-inc-advances-psychedelic-treatments-for-mental-health 2024-05-06T13:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/lyra-therapeutics-phase-3-enlighten-1-trial-for-chronic-rhinosinusitis-treatment-fails-to-meet-primary-endpoint 2024-05-06T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyra-therapeutics-phase-3-enlighten-1-trial-for-chronic-rhinosinusitis-treatment-fails-to-meet-primary-endpoint 2024-05-06T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/mediar-therapeutics-advances-fibrosis-treatment-with-phase-1-trial-of-mtx-463 2024-05-06T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mediar-therapeutics-advances-fibrosis-treatment-with-phase-1-trial-of-mtx-463 2024-05-06T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/idt-australia-secures-victorian-government-grant-to-establish-nation-s-first-commercial-adc-manufacturing-facility 2024-05-06T02:48:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/idt-australia-secures-victorian-government-grant-to-establish-nation-s-first-commercial-adc-manufacturing-facility 2024-05-06T02:48:51+00:00 weekly 0.7 https://trial.medpath.com/news/systematic-review-of-phase-ii-and-iii-clinical-trials-for-relapsing-multiple-sclerosis 2024-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systematic-review-of-phase-ii-and-iii-clinical-trials-for-relapsing-multiple-sclerosis 2024-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/off-the-shelf-allogeneic-car-t-therapies-show-promise-for-b-cell-malignancies 2024-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/off-the-shelf-allogeneic-car-t-therapies-show-promise-for-b-cell-malignancies 2024-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-announces-results-from-atlas-showing-robust-ugn-102-durability-of-response-in-new-and-recurrent-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-at-aua-2024 2024-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-announces-results-from-atlas-showing-robust-ugn-102-durability-of-response-in-new-and-recurrent-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-at-aua-2024 2024-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fresenius-kabi-launches-first-actemra-r-biosimilar-in-u-s-market-as-biosimilar-landscape-expands 2024-05-03T16:16:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fresenius-kabi-launches-first-actemra-r-biosimilar-in-u-s-market-as-biosimilar-landscape-expands 2024-05-03T16:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-approves-oxbryta-for-sickle-cell-disease-following-price-reduction-agreement 2024-05-03T01:38:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-approves-oxbryta-for-sickle-cell-disease-following-price-reduction-agreement 2024-05-03T01:38:05+00:00 weekly 0.7 https://trial.medpath.com/news/lifileucel-first-cellular-therapy-approved-for-cancer 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifileucel-first-cellular-therapy-approved-for-cancer 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gh-research-reports-first-quarter-2024-financial-results-and-business-updates 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gh-research-reports-first-quarter-2024-financial-results-and-business-updates 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fdas-accelerated-approval-of-sarepta-dmd-gene-therapy-comes-under-fire-biospace 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fdas-accelerated-approval-of-sarepta-dmd-gene-therapy-comes-under-fire-biospace 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ich-e6-r3-guidelines-set-to-transform-clinical-trial-quality-management-in-2025 2024-05-02T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ich-e6-r3-guidelines-set-to-transform-clinical-trial-quality-management-in-2025 2024-05-02T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-s-triple-combination-therapy-shows-promising-results-in-soft-tissue-sarcoma-phase-ii-trial 2024-05-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-s-triple-combination-therapy-shows-promising-results-in-soft-tissue-sarcoma-phase-ii-trial 2024-05-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atsena-therapeutics-reports-promising-results-for-xlrs-gene-therapy-using-novel-spreading-capsid 2024-05-01T14:48:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atsena-therapeutics-reports-promising-results-for-xlrs-gene-therapy-using-novel-spreading-capsid 2024-05-01T14:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-new-draft-guidance-on-allogeneic-cell-based-medical-products 2024-05-01T13:37:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-new-draft-guidance-on-allogeneic-cell-based-medical-products 2024-05-01T13:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-explores-dual-listing-on-senior-exchange-following-successful-clinical-trials 2024-05-01T09:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindbio-explores-dual-listing-on-senior-exchange-following-successful-clinical-trials 2024-05-01T09:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/newron-s-evenamide-shows-breakthrough-results-in-treatment-resistant-schizophrenia-phase-ii-iii-trials 2024-05-01T02:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newron-s-evenamide-shows-breakthrough-results-in-treatment-resistant-schizophrenia-phase-ii-iii-trials 2024-05-01T02:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/chime-biologics-and-mabgeek-achieve-mg-k10-ppq 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chime-biologics-and-mabgeek-achieve-mg-k10-ppq 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-announced-its-kras-g12c-inhibitor-reached-the-primary 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jacobio-pharma-announced-its-kras-g12c-inhibitor-reached-the-primary 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-florida-mrna-vaccine-shows-rapid-immune-response-against-glioblastoma-in-first-human-trial 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/university-of-florida-mrna-vaccine-shows-rapid-immune-response-against-glioblastoma-in-first-human-trial 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-makes-a-strong-start-to-2024-with-improving-outlook-for-the-year 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-makes-a-strong-start-to-2024-with-improving-outlook-for-the-year 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-secures-3-6-million-nih-grant-for-heart-failure-device-study 2024-04-30T12:36:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seastar-medical-secures-3-6-million-nih-grant-for-heart-failure-device-study 2024-04-30T12:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/eton-pharmaceuticals-announces-submission-to-fda-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-04-30T02:04:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eton-pharmaceuticals-announces-submission-to-fda-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-04-30T02:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/the-u-s-food-drug-administration-fda-approves-updated-lupkynis-r-voclosporin-label-to-include-long-term-data-from-the-aurora-clinical-program 2024-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-u-s-food-drug-administration-fda-approves-updated-lupkynis-r-voclosporin-label-to-include-long-term-data-from-the-aurora-clinical-program 2024-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-implements-historic-regulation-of-laboratory-developed-tests-with-new-final-rule 2024-04-29T09:41:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-implements-historic-regulation-of-laboratory-developed-tests-with-new-final-rule 2024-04-29T09:41:59+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-resubmits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem 2024-04-29T02:04:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-resubmits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem 2024-04-29T02:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-multiple-myeloma-marketscreener 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-multiple-myeloma-marketscreener 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-boston-biotechs-drug-for-ultra-rare-disease-of-immune-system-the-boston-globe 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-boston-biotechs-drug-for-ultra-rare-disease-of-immune-system-the-boston-globe 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-hercessitm-trastuzumab-strf-a-biosimilar-to-herceptin-r-trastuzumab-for-the-treatment-of-several-forms-of-her2-overexpressing-cancer 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-hercessitm-trastuzumab-strf-a-biosimilar-to-herceptin-r-trastuzumab-for-the-treatment-of-several-forms-of-her2-overexpressing-cancer 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ftc-intensifies-scrutiny-of-orange-book-patent-listings-in-pharmaceutical-industry 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ftc-intensifies-scrutiny-of-orange-book-patent-listings-in-pharmaceutical-industry 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-launches-beqvez-gene-therapy-for-hemophilia-b-with-novel-warranty-program-at-3-5m 2024-04-28T22:50:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-launches-beqvez-gene-therapy-for-hemophilia-b-with-novel-warranty-program-at-3-5m 2024-04-28T22:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-cdsco-rejects-pfizer-s-clinical-trial-waiver-for-multiple-myeloma-drug-elranatamab 2024-04-27T18:36:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-s-cdsco-rejects-pfizer-s-clinical-trial-waiver-for-multiple-myeloma-drug-elranatamab 2024-04-27T18:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pfizer-s-3-5-million-gene-therapy-beqvez-for-hemophilia-b-treatment 2024-04-26T11:02:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pfizer-s-3-5-million-gene-therapy-beqvez-for-hemophilia-b-treatment 2024-04-26T11:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/duchenne-muscular-dystrophy-gene-therapy-trial-shows 2024-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duchenne-muscular-dystrophy-gene-therapy-trial-shows 2024-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv 2024-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv 2024-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-personalized-mrna-vaccine-for-melanoma-enters-uk-clinical-trials 2024-04-25T23:45:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-personalized-mrna-vaccine-for-melanoma-enters-uk-clinical-trials 2024-04-25T23:45:21+00:00 weekly 0.7 https://trial.medpath.com/news/tease-3-study-reports-positive-interim-data-for-stargardt-disease-treatment 2024-04-25T16:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tease-3-study-reports-positive-interim-data-for-stargardt-disease-treatment 2024-04-25T16:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/starton-therapeutics-completes-enrollment-for-star-lld-phase-1b-trial-in-multiple-myeloma-reports-superior-safety-profile 2024-04-25T12:33:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/starton-therapeutics-completes-enrollment-for-star-lld-phase-1b-trial-in-multiple-myeloma-reports-superior-safety-profile 2024-04-25T12:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/xaira-therapeutics-launches-with-record-1-billion-funding-to-revolutionize-ai-driven-drug-discovery 2024-04-25T00:16:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xaira-therapeutics-launches-with-record-1-billion-funding-to-revolutionize-ai-driven-drug-discovery 2024-04-25T00:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/car-nk-cell-therapy-shows-promise-as-safer-alternative-to-car-t-with-comparable-efficacy-in-early-clinical-trials 2024-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-nk-cell-therapy-shows-promise-as-safer-alternative-to-car-t-with-comparable-efficacy-in-early-clinical-trials 2024-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-cancer-treatment-the-promise-of-oncolytic-virotherapy-combinations 2024-04-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-cancer-treatment-the-promise-of-oncolytic-virotherapy-combinations 2024-04-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-announces-positive-preliminary-topline-results-from-tacti-003-cohort-b 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-announces-positive-preliminary-topline-results-from-tacti-003-cohort-b 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mirvetuximab-soravtansine-gynx-approved-for-ovarian-cancer 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirvetuximab-soravtansine-gynx-approved-for-ovarian-cancer 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-new-approval-for-wegovy-opens-medicare-coverage-for-millions-with-obesity 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-new-approval-for-wegovy-opens-medicare-coverage-for-millions-with-obesity 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-immunitybio-s-anktiva-for-bladder-cancer-marking-major-milestone-for-soon-shiong-s-immunotherapy-approach 2024-04-23T20:55:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-immunitybio-s-anktiva-for-bladder-cancer-marking-major-milestone-for-soon-shiong-s-immunotherapy-approach 2024-04-23T20:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-shows-promise-as-first-pharmaceutical-treatment-for-obstructive-sleep-apnea-in-obesity 2024-04-23T17:13:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-shows-promise-as-first-pharmaceutical-treatment-for-obstructive-sleep-apnea-in-obesity 2024-04-23T17:13:02+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-approved-in-europe-for-non-small-cell-lung-cancer-treatment 2024-04-23T16:00:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tislelizumab-approved-in-europe-for-non-small-cell-lung-cancer-treatment 2024-04-23T16:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/actinogen-xanamia-acw0009-phase-2b-trial-for-mci-and-mild-alzheimer-s-disease 2024-04-23T03:38:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actinogen-xanamia-acw0009-phase-2b-trial-for-mci-and-mild-alzheimer-s-disease 2024-04-23T03:38:04+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-rilzabrutinib-luna-3-phase-3-study-met 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-rilzabrutinib-luna-3-phase-3-study-met 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-partners-with-msd-to-test-novel-bispecific-antibody-bh3120-in-combination-with-keytruda 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-partners-with-msd-to-test-novel-bispecific-antibody-bh3120-in-combination-with-keytruda 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-alvotech-teva-s-ustekinumab-biosimilar-for-psoriasis-and-psoriatic-arthritis 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-alvotech-teva-s-ustekinumab-biosimilar-for-psoriasis-and-psoriatic-arthritis 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-immunitybio-s-bladder-cancer-treatment-los-angeles-times 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-immunitybio-s-bladder-cancer-treatment-los-angeles-times 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-pfizer-s-emblaveo-first-in-class-antibiotic-for-multi-drug-resistant-infections 2024-04-22T23:23:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approves-pfizer-s-emblaveo-first-in-class-antibiotic-for-multi-drug-resistant-infections 2024-04-22T23:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-s-rett-syndrome-drug-under-priority-review-in-canada 2024-04-22T13:15:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acadia-s-rett-syndrome-drug-under-priority-review-in-canada 2024-04-22T13:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-provides-regulatory-update-on-pz-cel 2024-04-22T04:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abeona-therapeutics-provides-regulatory-update-on-pz-cel 2024-04-22T04:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/fate-therapeutics-treats-first-lupus-patient-with-off-the-shelf-car-t-cell-therapy-ft819 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fate-therapeutics-treats-first-lupus-patient-with-off-the-shelf-car-t-cell-therapy-ft819 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-allows-for-treatment-free-period-in-early-r-r-multiple 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilta-cel-allows-for-treatment-free-period-in-early-r-r-multiple 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-cheap-drug-may-slow-down-aging-a-study-will-determine-if-it-works-npr 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-cheap-drug-may-slow-down-aging-a-study-will-determine-if-it-works-npr 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ind-for-arbor-biotechnologies-abo-101-gene-editing 2024-04-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-ind-for-arbor-biotechnologies-abo-101-gene-editing 2024-04-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-tool-predicts-responses-to-cancer-therapy-using-single-cell-omics 2024-04-18T19:02:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-tool-predicts-responses-to-cancer-therapy-using-single-cell-omics 2024-04-18T19:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-pembrolizumab-shows-improved-overall-survival-in-keynote-564-trial-for-ccrcc 2024-04-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-pembrolizumab-shows-improved-overall-survival-in-keynote-564-trial-for-ccrcc 2024-04-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scandion-oncology-announces-rights-issue-to-raise-approximately-sek-60-million 2024-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scandion-oncology-announces-rights-issue-to-raise-approximately-sek-60-million 2024-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nexcella-an-immix-biopharma-subsidiary-on-track-to-dose-nxc-201-patients-in-united-states-biospace 2024-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nexcella-an-immix-biopharma-subsidiary-on-track-to-dose-nxc-201-patients-in-united-states-biospace 2024-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-announces-phase-iib-clinical-trial-listing-on-the-australian-new-zealand-clinical-trials-registry-anzctr 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-biomed-announces-phase-iib-clinical-trial-listing-on-the-australian-new-zealand-clinical-trials-registry-anzctr 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ryzumvi-for-treating-drug-induced-mydriasis 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ryzumvi-for-treating-drug-induced-mydriasis 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-ab-new-publication-highlights-safety-and 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-ab-new-publication-highlights-safety-and 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-announces-latest-results-from-axess-trials-to-be-presented-at 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-announces-latest-results-from-axess-trials-to-be-presented-at 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-announces-phase-2-clinical-trial-update-first-patient-completes-dosing-with-personalized-cancer-vaccine-evx-01 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaxion-announces-phase-2-clinical-trial-update-first-patient-completes-dosing-with-personalized-cancer-vaccine-evx-01 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-sets-sights-on-launching-25-new-treatments-by-2030 2024-04-16T15:00:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-sets-sights-on-launching-25-new-treatments-by-2030 2024-04-16T15:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/two-major-breakthroughs-in-fragile-x-syndrome-treatments 2024-04-16T13:33:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-major-breakthroughs-in-fragile-x-syndrome-treatments 2024-04-16T13:33:24+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-presents-positive-18-month-phase-ib-trial-results-for-ab-1005-gene-therapy-in-parkinsons-disease 2024-04-16T12:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/askbio-presents-positive-18-month-phase-ib-trial-results-for-ab-1005-gene-therapy-in-parkinsons-disease 2024-04-16T12:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-advances-in-endometrial-cancer-focus-shifts-to-pmmr-disease-following-success-in-dmmr-population 2024-04-16T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-advances-in-endometrial-cancer-focus-shifts-to-pmmr-disease-following-success-in-dmmr-population 2024-04-16T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/volastra-therapeutics-initiates-phase-ib-trial-of-sovilnesib-for-platinum-resistant-ovarian-cancer 2024-04-16T11:00:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/volastra-therapeutics-initiates-phase-ib-trial-of-sovilnesib-for-platinum-resistant-ovarian-cancer 2024-04-16T11:00:25+00:00 weekly 0.7 https://trial.medpath.com/news/cancervax-announces-promising-new-drug-to-treat-a-deadly-children-s-cancer 2024-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancervax-announces-promising-new-drug-to-treat-a-deadly-children-s-cancer 2024-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spatial-comparison-of-molecular-features-associated-with 2024-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spatial-comparison-of-molecular-features-associated-with 2024-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-announces-advancement-of-sanofi-developed-nk-cell-engager-sar443579-iph6101-to-phase-2-for-blood-cancer-patients 2024-04-15T13:56:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innate-pharma-announces-advancement-of-sanofi-developed-nk-cell-engager-sar443579-iph6101-to-phase-2-for-blood-cancer-patients 2024-04-15T13:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/11-clinical-trials-that-have-researchers-excited-in-2024 2024-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/11-clinical-trials-that-have-researchers-excited-in-2024 2024-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/norgine-b-v-submits-marketing-authorisation-application-via-project 2024-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/norgine-b-v-submits-marketing-authorisation-application-via-project 2024-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-azn-voydeya-gets-fda-nod-mrk-kras-inhibitor-enters-phase 2024-04-12T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-roundup-azn-voydeya-gets-fda-nod-mrk-kras-inhibitor-enters-phase 2024-04-12T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/why-is-viatris-vtrs-down-3-5-since-last-earnings-report 2024-04-12T13:08:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-is-viatris-vtrs-down-3-5-since-last-earnings-report 2024-04-12T13:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-aldx-stock-rallies-43-in-one-week-here-s-why 2024-04-12T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-aldx-stock-rallies-43-in-one-week-here-s-why 2024-04-12T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-rsv-shot-meets-goals-in-trial-of-high-risk-adults-under-age-60 2024-04-12T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-rsv-shot-meets-goals-in-trial-of-high-risk-adults-under-age-60 2024-04-12T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-vrtx-begins-rolling-nda-filing-for-acute-pain-drug 2024-04-12T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-vrtx-begins-rolling-nda-filing-for-acute-pain-drug 2024-04-12T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/can-amivantamab-and-lazertinib-replace-osimertinib-in 2024-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-amivantamab-and-lazertinib-replace-osimertinib-in 2024-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-odac-recognizes-mrd-as-an-accepted-end-point 2024-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-odac-recognizes-mrd-as-an-accepted-end-point 2024-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-breakthrough-device-designation-for-ptau217-blood-test-to-aid-in-early-alzheimers-diagnosis 2024-04-11T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-receives-fda-breakthrough-device-designation-for-ptau217-blood-test-to-aid-in-early-alzheimers-diagnosis 2024-04-11T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/vigeneron-doses-first-patient-in-phase-1b-clinical-trial-of-vg901-for-retinitis-pigmentosa-treatment 2024-04-11T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vigeneron-doses-first-patient-in-phase-1b-clinical-trial-of-vg901-for-retinitis-pigmentosa-treatment 2024-04-11T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-parliament-approves-major-pharmaceutical-reform-package-with-modified-exclusivity-terms 2024-04-11T00:03:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-parliament-approves-major-pharmaceutical-reform-package-with-modified-exclusivity-terms 2024-04-11T00:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimers-trial-brings-at-risk-patients-hope-for-the-future-but-new-doubts-in-the-present-the-globe-and-mail 2024-04-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimers-trial-brings-at-risk-patients-hope-for-the-future-but-new-doubts-in-the-present-the-globe-and-mail 2024-04-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-hope-for-men-with-metastatic-prostate-cancer 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-hope-for-men-with-metastatic-prostate-cancer 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/torl-biotherapeutics-announces-158-million-oversubscribed-series-b-2-financing-to-advance-the-clinical-development-of-its-novel-antibody-drug-conjugate-adc-oncology-pipeline 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/torl-biotherapeutics-announces-158-million-oversubscribed-series-b-2-financing-to-advance-the-clinical-development-of-its-novel-antibody-drug-conjugate-adc-oncology-pipeline 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-tigris-trial-update-the-globe-and-mail 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-provides-tigris-trial-update-the-globe-and-mail 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aacr-2024-linvoseltamab-demonstrates-promising-results-in-heavily-pre-treated-multiple-myeloma-patients 2024-04-09T16:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aacr-2024-linvoseltamab-demonstrates-promising-results-in-heavily-pre-treated-multiple-myeloma-patients 2024-04-09T16:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-can-help-reduce-heart-failure-symptoms-even-when-people-don-t-lose-as-much-weight 2024-04-09T15:29:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wegovy-can-help-reduce-heart-failure-symptoms-even-when-people-don-t-lose-as-much-weight 2024-04-09T15:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/genomics-market-set-to-reach-157-47-billion-by-2033-driven-by-personalized-medicine-and-government-funding 2024-04-09T05:09:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomics-market-set-to-reach-157-47-billion-by-2033-driven-by-personalized-medicine-and-government-funding 2024-04-09T05:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/artificial-intelligence-analysis-of-dna-fragmentomes-and-protein-biomarkers-noninvasively-detects-ovarian-cancer-news-releases-aacr 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artificial-intelligence-analysis-of-dna-fragmentomes-and-protein-biomarkers-noninvasively-detects-ovarian-cancer-news-releases-aacr 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-cort-completes-enrollment-in-ovarian-cancer-study 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-cort-completes-enrollment-in-ovarian-cancer-study 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-efficacy-of-tace-combined-with-tkis-and-icis-in-treating-hcc 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhanced-efficacy-of-tace-combined-with-tkis-and-icis-in-treating-hcc 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combination-immunotherapy-strategies-show-promise-in-overcoming-nsclc-treatment-resistance 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-immunotherapy-strategies-show-promise-in-overcoming-nsclc-treatment-resistance 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/augustine-therapeutics-raises-eur78-million-series-a-to-advance-novel-hdac6-inhibitor-for-charcot-marie-tooth-disease 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/augustine-therapeutics-raises-eur78-million-series-a-to-advance-novel-hdac6-inhibitor-for-charcot-marie-tooth-disease 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-could-reach-beyond-cancer-medicine-net 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-could-reach-beyond-cancer-medicine-net 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/supernus-provides-regulatory-update-for-spn-830 2024-04-08T22:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/supernus-provides-regulatory-update-for-spn-830 2024-04-08T22:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/oric-pharmaceuticals-unveils-promising-cancer-drug-data-at-aacr-meeting 2024-04-08T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oric-pharmaceuticals-unveils-promising-cancer-drug-data-at-aacr-meeting 2024-04-08T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-immunotherapy-market-set-to-reach-usd-296-billion-by-2033-growing-at-8-9-cagr 2024-04-08T11:23:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-immunotherapy-market-set-to-reach-usd-296-billion-by-2033-growing-at-8-9-cagr 2024-04-08T11:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome 2024-04-08T04:04:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome 2024-04-08T04:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/uc-davis-health-pioneers-novel-heart-valve-repair-with-newly-approved-device 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uc-davis-health-pioneers-novel-heart-valve-repair-with-newly-approved-device 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-shorlas-oral-liquid-leukaemia-drug-nda-pharmaceutical-technology 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-shorlas-oral-liquid-leukaemia-drug-nda-pharmaceutical-technology 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-parp-inhibitor-shows-promise-in-treating-hrr-deficient-breast-cancer 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-parp-inhibitor-shows-promise-in-treating-hrr-deficient-breast-cancer 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-s-ocu400-becomes-first-gene-therapy-to-enter-phase-3-for-broad-retinitis-pigmentosa-treatment 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-s-ocu400-becomes-first-gene-therapy-to-enter-phase-3-for-broad-retinitis-pigmentosa-treatment 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shorla-oncology-announces-fda-filing-acceptance-of-new-drug 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorla-oncology-announces-fda-filing-acceptance-of-new-drug 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-most-cancer-drugs-with-accelerated-fda-approval-fail-to-demonstrate-clinical-benefit-after-five-years 2024-04-07T18:06:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-most-cancer-drugs-with-accelerated-fda-approval-fail-to-demonstrate-clinical-benefit-after-five-years 2024-04-07T18:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-mrna-vaccine-shows-promise-in-fighting-pancreatic-cancer 2024-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-mrna-vaccine-shows-promise-in-fighting-pancreatic-cancer 2024-04-07T00:00:00+00:00 weekly 0.7